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Abstract 
 
Mark W. Gramling 
 
Serine Proteases and Serine Protease Inhibitors in Breast Cancer Cell Pathophysiology 
(Under the direction of Frank C. Church, Ph.D.) 
 
Hemostasis and fibrinolysis are mediated by serine proteases and regulated by serine 
protease inhibitors, or serpins.  There is a growing body of evidence that a few of these serine 
proteases and serpins have direct effects on cancer pathophysiology.  Activated protein C 
(APC) is a serine protease that limits excessive clot formation by catalyzing inactivation of 
other coagulation factors.  APC has also been shown to have non-hemostatic functions 
related to inflammation, angiogenesis, and cell migration.  Therefore, we investigated the 
mechanisms by which APC could promote angiogenesis and breast cancer invasion.  We 
confirmed that proteolytically active APC promotes angiogenesis by a mechanism dependent 
on matrix metalloprotease (MMP) activity and EGFR transactivation.  Furthermore, we show 
that APC promotes breast cancer cell invasion by a similar mechanism and also show that 
APC induced cancer cell invasion is dependent upon activation of intracellular signaling 
pathways, specifically MAPK and PI3K signaling.  Another serine protease, urokinase 
plasminogen activator (uPA), initiates fibrinolysis by activating plasmin – the protease which 
catalyzes degradation of fibrin clots.  uPA activity is inhibited by the serpin plasminogen 
activator inhibitor 1 (PAI-1).  Outside of fibrinolysis, uPA and PAI-1 are regulators of tumor 
cell motility through the focusing of their activities at the cancer cell surface.  In breast 
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cancer, clinical studies have demonstrated that elevation of both uPA and PAI-1 in tumor 
biopsies is predictive of poor prognosis.  Therefore, we utilized breast cancer cell lines to 
investigate a possible direct mechanism whereby elevation of both uPA and PAI-1 could 
provide a survival advantage to breast cancer cells.  Utilizing inhibitors of uPA and PAI-1 
activity, as well as stable knockdown of each factor individually, we demonstrate that uPA 
promotes cell growth via activation of MAPK signaling.  We also demonstrate that the 
catalytic function of both uPA and PAI-1 promote cell growth.  We found PAI-1 is a key 
regulator of both MAPK signaling and anti-apoptotic PI3K signaling.   Finally, we found that 
PAI-1 protects breast cancer cells from apoptosis inducing chemotherapeutic drugs, 
suggesting a direct mechanism whereby PAI-1 elevation is associated with poor prognosis in 
breast cancer.   
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
Acknowledgements 
 
 This dissertation represents the culmination of my work over the past four years.  
While there have been difficult times, I have truly enjoyed my time here in Chapel Hill and 
in this laboratory.  I will certainly miss this place as I move on to the next step in life.  There 
are a few people who deserve recognition for their contributions to my work and support in 
my life. 
  
 I would like to first acknowledge my thesis committee members Drs. Buddy 
Weissman, Marila-Cordeiro Stone, Young Whang, and Blossom Damania.  I greatly 
appreciate their time contributing to my development as a scientist.  It was a pleasure 
working with all of you and I thank you for pushing me to produce a thesis for which I am 
proud.  I would like to especially thank Buddy Weissman for his time when I rotated in his 
lab and his advice.   
  
 I would like to thank some former members of the Church lab.  When I joined the lab 
as a rotating student, I started working with Lea Beaulieu.  She served as my mentor and we 
ultimately developed a great friendship and she was always there when I needed her.  It was 
excellent working with Jill Rau.  Jill is a wonderful friend and a joy to be around.  I also 
enjoyed my time working with Jennifer Carter Scull.  It’s always a good time talking with 
Jennifer and I look forward to spending time with her and her husband when I move to 
Nashville.     As postdocs Drs. Yolanda Fortenberry and Jen Gibbons are excellent lab mates.  
  
 I also had the opportunity to work with three UNC undergraduate students – Leah 
Hawkins, Emir Sandhu, and Julie Suyama.  It was a great experience working with all of 
them.  I especially enjoyed lots of fun nights outside the lab with Leah and Emir.  They have 
all moved on to top notch medical schools and I know they will be successful.   
  
 One of the reasons I joined the pathology program here was the excellent graduate 
students I met in the interview process.  I would like to acknowledge former students like Jen 
Jahn, Hunter Best, Robby Campbell, Lee Mangiante, Dean Staus, Jeremiah Hinson, and all 
the rest of those who welcomed me to the department.  My time adjusting to graduate school 
was also aided by excellent guidance from Dr. Alisa Wolberg with whom I did my first 
rotation.  I would also like to thank Matt Medlin and Avani Pendse who came to the 
department the same time I did for their friendship.  I will certainly miss nights out with 
Medlin as he has helped me through the ups and downs of the past years.    
 
 I’d be remiss if I did not acknowledge my time working with the dental school.  I 
thank Dr. Susan Hadler for giving me the opportunity to TA histology for 4 years.  I always 
looked forward to lab and working fellow graduate student Rupan Sandhu.  Over the years 
I’ve developed some good friends in the dental program and would like to thank former 
dental student (and next door neighbor) Dan Siceloff for his friendship over the years.   
 
 Now for the current lab.  I’d like to thank our new technician Leana Lefrapper for her 
hard work helping me sprint to the finish and I wish our new postdoc Chantelle Rein all the 
best as she develops her career.  Dr. Mac Monroe has been an excellent colleague of our lab 
vi 
 
and always is prepared with sage advice.  Troy McEachron is a great scientist and I wish him 
well as he too will be graduating soon.  It’s been wonderful getting to know our 
undergraduate Courtney Sorensen who is great to have around.  Finally, I would like to 
especially thank Jessica Cardenas.  I will truly miss Jessica and I am lucky to have gained 
such a great friend.  I sincerely thank her for all of her support.  Overall, the lab throughout 
my time here has been like a second family.   
 
 Through all my years in his laboratory, Frank has been an excellent advisor.  He is 
uniquely dedicated to helping his graduate students and also goes above and beyond with his 
other contributions to undergraduate education.  It took me some time to really develop the 
skills to become a disciplined scientist.  Throughout it all however, Frank was always patient 
and always supportive of my endeavors.  I sincerely thank Frank for allowing me to pursue 
my own crazy idea of a project at the beginning and having my back to allow me to finish up 
that project and move on with my career at the end.  We’ve had lots of good times from 
Durham Bulls baseball games to sharing a room at conferences.  In sum, I want to 
acknowledge Frank is an excellent mentor, scientist, and person.    
    
 I am certain I would not have reached this point without the love and support of my 
family.  My father and mother, Roger and Marylin Gramling, are steadfast in their support of 
me.  Whether its emotional, practical, or financial, they have always been there.  Through all 
of the my tougher times over the past years, times when my confidence was shaken, they 
always believed in me.  I would also like to acknowledge my brother David as my 
inspiration; although I’ve missed him during his four deployments, I’m proud of his service 
to this country.    
 
 Finally, I would like to thank my fiancé Jennifer Muller.  While many others have 
supported me over the years, most are not called on 7 days a week.  For every success she 
says she is proud, and for every time I’m struggling she assures me everything will be fine 
and I can do it.  I don’t know where I would be without her.  I am looking forward to starting 
the next chapter of my life with her by my side.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
 
 
 
 
Table of Contents 
Page 
List of Figures………………………………………………………………………………...ix 
 
List of Abbreviations………………………………………………………………………...xii 
 
Chapter 
 
 I. Introduction……………………………………………………………………1 
 II. Thrombin, Activated Protein C, and Urokinase Plasminogen Activator: 
  The role of coagulation serine proteases in cancer pathophysiology…………6 
   Abstract………………………………………………………………..7 
   Introduction……………………………………………………………8 
   Thrombin………………………………………………………………9 
   Activated Protein C…………………………………………………..13 
   Urokinase plasminogen activator…………………………………….16 
   Conclusions…………………………………………………………..22 
   Literature Cited………………………………………………………23 
 III. Activated Protein C Enhances Cell Motility of MDA-MB-231 Breast  
  Cancer Cells and Endothelial Cells by Intracellular Signal Transduction…...34 
    
   Abstract………………………………………………………………34 
   Introduction…………………………………………………….…….35 
   Materials and Methods………………………………………….……38 
   Results……………………………………………………….……….44 
   Discussion……………………………………………………………59 
   Literature Cited………………………………………………………64 
viii 
 
 IV. Plasminogen Activator Inhibitor-1 is an Aggregate Response Factor with  
  Pleiotropic Effects on Cell Signaling in Vascular Disease and the Tumor  
  Microenvironment……………………………………………………………69 
    
   Abstract………………………………………………………………70 
    
   Introduction…………………………………………………………..71 
    
   Pathologic consequences of PAI-1 expression explained by  
   Traditional paradigms…………………………………………….….74 
    
   Pathologic consequences of PAI-1 expression not explained by  
   traditional paradigms………………………………………………...75 
    
   Conclusion…………………………………………………………...79 
    
   Literature Cited………………………………………………………81 
  
 V.  Urokinase-type Plasminogen Activator and Plasminogen Activator 1  
  modulate proliferation and sensitivity to apoptosis in breast cancer cells…...87 
    
   Abstract………………………………………………………………88 
    
   Introduction……………………………………………………….….89 
    
   Materials and Methods……………………………………………….91 
    
   Results…………………………………………………………….….96 
    
   Discussion…………………………………………………………..123 
    
   Literature Cited……………………………………………….…….130 
  
 V. Discussion and Future Directions…………………………………………….…136 
    
   Literature Cited………………………………………………….….145 
 
 Appendix……………………………….…………………………………………...146 
 
 
 
 
ix 
 
List of Figures 
Figure  
                     Page 
2.1    The Plasminogen Activator System at the cell surface……………………….………..20 
 
3.1 APC promotes HUVEC invasion, chemotaxis, tube formation and murine aortic  
 ring sprouting…………………………………….…………………………………….47 
 
3.2 APC promotes sprout formation of murine aortic rings through MMPs and EGFR…..49 
 
3.3 APC promotes invasion of the MDA-MB-231 cells by binding to EPCR and PAR-1..50 
 
3.4 APC promotes chemotaxis of MDA-MB-231 cells by activating both the PI3K and 
MAPK pathways……………………………………………………………………….52 
 
3.5 APC promoted invasion and chemotaxis of MDA-MB-231 cells is dependent upon 
activation of EGFR…………………………………………………………………….54 
 
3.6 APC promoted invasion of MDA-MB-231 cells is dependent upon MMP-2 and  
 MMP-9 degradation of the extracellular matrix……………………………………….56 
 
3.7 APC does not increase invasion of the MDA-MB-231 cells through the plasminogen 
activator system………………………………………………………………………..58 
 
4.1 PAI-1 has been implicated in modulating a variety of physiological and 
pathophysiological processes…………………………………………………………..80 
 
5.1 Effect of disruption of the plasminogen activator system on invasion and viability  
 of MDA-MB-231 cells…………………………………………………………………97 
 
5.2 PI3K and MAPK signaling modulate uPA and PAI-1 expression…………………….99 
 
5.3 Characterization of stable lentiviral mediated knockdown of uPA in MDA-MB-231 cells….100 
 
5.4 Cell-surface associated uPA activity and extracellular matrix adhesion in  
 MDA-MB-231 cells with stable uPA knockdown…………………………………....102 
 
5.5 Effect of stable uPA knockdown in MDA-MB-231 cells on growth in a three 
dimensional matrix……………………………………………………………………103 
 
5.6 Effect of stable uPA knockdown on MDA-MB-231 cells viability in low serum  
 and sensitivity to chemotherapeutic agents……………………………………..…….105 
 
x 
 
5.7 Effect of inhibition of uPA and PAI-1 activity on the viability of MDA-MB-231  
 and MDA-MB-436 cells in low serum……………………………………….………106 
 
5.8 Effect of uPA and PAI-1 activity on growth in a three dimensional matrix……….…107 
 
5.9 Effect of inhibition of uPA and PAI-1 activity on the activity of PI3K and MAPK…109 
 
5.10 Characterization of stable lentiviral mediated knockdown of PAI-1 in  
 MDA-MB-231 cells………………………………………………………...……...…110 
 
5.11 Cell-surface associated uPA activity and extracellular matrix adhesion in  
 MDA-MB-231 cells with stable PAI-1 knockdown……………………………..…...112 
 
5.12 Effect of stable PAI-1 knockdown in MDA-MB-231 cells on growth in a three 
dimensional matrix……………………………………………………………………112 
 
5.13 Characterization of MDA-MB-231 cells expressing PAI-1shRNA#5……………….113 
 
5.14 Effect of stable PAI-1 knockdown in MDA-MB-231 cells on viability in low serum.116 
 
5.15 Effect of stable PAI-1 knockdown on PI3K and MAPK activity…………………….117 
 
5.16 Assessment of basal proliferative capacity and apoptosis in MDA-MB-231 cells  
 with stable PAI-1 knockdown………………………………………………………...119 
 
5.17 Chemotherapeutic sensitivity of MDA-MB-231 cells with stable PAI-1 knockdown.121 
 
5.18 Sensitization of MDA-MB-436 cells to chemotherapeutic agents by PAI-1 activity 
inhibition……………………………………………………………………………...122 
 
5.19 Working model of MAPK and PI3K signaling modification by PAI-1……………...128 
 
 
 
 
 
 
 
 
xi 
 
List of Abbreviations 
APC    Activated protein C 
ATF    Amino-terminal fragment 
BBE    Bovine brain extract 
BME    Basement membrane extract 
bFGF    Basic fibroblast growth factor 
BSA    Bovine serum albumin 
DNA    Deoxyribonucleic acid 
ECM    Extracellular Matrix 
EGF    Epidermal growth factor 
EGFR    Epidermal growth factor receptor 
eNOS    Endothelial nitric oxide synthase 
EPCR    Endothelial protein C receptor 
ER    Estrogen receptor 
ERK    Extracellular regulated kinase 
FAK    Focal adhesion kinase 
FBS    Fetal bovine serum 
FN    fibronectin 
GPCR    G-protein coupled receptor 
GPI    glycophosphotidyl-inositol 
HB-EGF   Heparin-bound epidermal growth factor 
HER2    Human epidermal  growth factor receptor 2 
HUVEC   Human umbilical vein endothelial cells 
xii 
 
IL    Interleukin 
JNK    Jun N-terminal kinase 
LOE    Level of evidence 
LRP    Low density lipoprotein like receptor 
MAPK    Mitogen activated protein kinase 
MCP-1   Monocyte chemotactic protein-1 
M-MLV   Mouse mammary leukemia virus 
MMP    Matrix metalloprotease 
MTT    3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NFB    Nuclear factor kappa-light-chain-enhancer of activated B cells 
PAI-1    Plasminogen activator inhibitor 1 
PAGE    Pulsed applied gel electrophoresis 
PAR    Protease activated  receptor 
PBS    Phosphate buffered saline 
PC    Protein C 
PCR    Polymerase chain reaction 
PI3K    Phosphoinositide-3 kinase 
PKA    Protein kinase A 
PKC    Protein kinase C 
PR    Progesterone recptor 
PS    Protein S 
RNA    Ribonucleic acid 
RNAi    Ribnonucleic acid interference 
xiii 
 
S1P    Sphingosine-1 phosphate 
SDS    Sodium dodecyl sulfate 
serpin    Serine protease inhibitor  
shRNA   short hairpin ribonucleic acid 
TACE    tumor necrosis factor alpha converting enzyme 
TF    Tissue Factor 
TGF    Transforming growth factor 
TM    Thrombomodulin 
TRAIL   TNF-related apoptosis-inducing ligand 
tPA    tissue-type plasminogen activator 
TNF    Tumor necrosis factor 
uPA    urokinase-type plasminogen activator 
uPAR    urokinase-type plasminogen activator receptor 
VEGF    Vascular endothelial growth factor 
VN    Vitronectin 
vWF    Von Willebrand factor  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Chapter I 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Breast cancer is the second leading cause of cancer related death for women in the 
U.S., second only to lung cancer.  A diagnosis of 207,090 new cases of breast cancer is 
predicted for 2010.  Based on data gathered from 1996 to 2003, the five year survival rate for 
breast cancer that is localized at the time of diagnosis is approximately 98%.  However, if at 
time of diagnosis breast cancer has spread regionally, the 5 year survival rate falls to 84%.  In 
cases where distant metastases are present at time of diagnosis, the 5 year survival rate is 
very low – approximately 23%.  Among women, breast cancer accounts for 15% of cancer 
related deaths, predicted to account for 40,730 breast cancer related deaths for women in 
2010 [1].    
 Death cancer rates have declined steadily in the past 20 years in part through 
increased use of mammography for early detection.  In addition, the development of targeted 
therapies in breast cancer to complement traditional chemotherapeutic regimens has 
improved treatment.  The development of a monoclonal antibody targeting human epidermal 
growth factor receptor 2 (HER2) has proven effective in treatment of women with surgically 
removed and metastatic HER2 positive breast cancer [2,3].  The development of hormonal 
therapy for women with estrogen receptor (ER) and/or progesterone receptor (ER) breast 
cancer has also improved survival and recurrence rates [4,5].   The success of these targeted 
therapies highlights the need for continued research into novel factors that drive breast cancer 
pathophysiology.  This is important for both identifying new prognostic indicators as well as 
potential targets for therapeutic intervention. 
 There is an emerging body of evidence that serine proteases and serine protease 
inhibitors, which regulate hemostasis (clot formation) and fibrinolysis (clot dissolution), also 
have functions in cancer physiology.  More specifically, the hemostatic serine proteases 
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thrombin and activated protein C (APC) have been shown to regulate processes that can 
contribute to cancer growth and metastasis, including angiogenesis, cancer cell motility, and 
tumor growth and resistance to apoptosis.  The serine protease urokinase-type plasminogen 
activator (uPA), which initiates fibrinolysis, also has been implicated in promoting cancer 
cell growth and metastasis.  Intriguingly, there is some evidence which suggests the serine 
protease inhibitor plasminogen activator inhibitor 1 (PAI-1), which inhibits uPA, also 
contributes to tumor growth and metastasis.  Based on these observations, in this study we 
closely examined the roles of PAI-1, APC, and uPA in breast cancer cell pathophysiology.   
 In Chapter II, I review the literature on the role of the serine proteases thrombin, 
APC, and uPA in cancer pathology.  Thrombin, which in the vasculature initiates clot 
formation, has demonstrated pro-angiogenic functions and can also stimulate tumor cell 
motility – capacities that contribute to metastasis.  APC, which inhibits clot formation, has 
activities related to cancer pathology that are either parallel or opposite to thrombin, 
depending on experimental context.  This is intriguing given that thrombin and APC target 
the same cell receptor on endothelial cells and cancer cells.  Multiple studies have shown that 
uPA coordinates a wide array of activities that contribute to tumor growth and metastasis.    
 Chapter III is an examination of the mechanisms by with the serine protease APC 
could contribute to breast cancer biology [6].  We demonstrate that APC promotes 
angiogenesis using in vitro and ex vivo models.  Our findings also show that the APC 
promotes cancer cell invasion by a mechanism far more complex than suggested in previous 
reports.  We show that APC stimulates breast cancer cell motility and invasion via a 
mechanism that is dependent upon both extracellular protease activity and the activation of 
intracellular signaling pathways. 
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 Chapter IV is a review of the pleotrophic activities of the serine protease inhibitor 
PAI-1 in the pathophysiology of various diseases [7].  PAI-1 has been implicated in playing a 
role in diseases such as atherosclerosis, restenosis, and cancer.  For some disease states, the 
capacity of PAI-1 to inhibit the serine protease uPA seems to fully explain its role.  However, 
in other cases, the protease inhibitor capacity of PAI-1 does not seem sufficient to explain its 
role.  Therefore, we review recent evidence suggesting PAI-1 can also participate in 
processes related to motility, proliferation, and sensitivity to apoptosis.   
 In Chapter V, I examine the contributions of both PAI-1 and uPA to the viability of 
breast cancer cells.  Basically, this study is a focused attempt to address a long standing 
paradox in the field, known as the “PAI-1 Paradox.”  Multiple studies have indicated that 
elevation of both uPA and PAI-1 are predictors of lower disease survival, increased 
recurrence, and increased metastasis.  The paradox arises because it is unclear why elevated 
PAI-1 levels would be associated with metastasis if the primary role of PAI-1 is only to 
inhibit the proteolytic events catalyzed by uPA.  We confirmed uPA promotes cell growth 
and proliferative signaling, as shown by others in other forms of cancer.  Uniquely, we also 
show that PAI-1 promotes proliferative and anti-apoptotic signaling as well as protects breast 
cancer cells from apoptosis inducing chemotherapeutic agents.   
 Finally, in Chapter VI, I address the significance of our findings to breast cancer 
pathophysiology and discuss future directions to expand upon these findings.     
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Abstract 
The serine proteases thrombin, activated protein C (APC), and urokinase-type 
plasminogen activator (uPA) are well documented regulators of hemostasis and fibrinolysis via 
their canonical targets in the coagulation and fibrinolytic pathways.  Research into activities of 
these proteases outside of  hemostasis-fibrinolysis has revealed their capacity to participate in 
key processes in cancer pathophysiology.  For thrombin and APC, cleavage of transmembrane 
protease-activated receptors (PARs) has been demonstrated to activate intracellular signaling 
pathways that up-regulate various growth factors and cytokines to promote angiogenesis. 
Thrombin and APC have also been shown to directly activate signaling pathways that promote 
growth and motility of both endothelial and cancer cells.  uPA, in conjunction with its cognate 
cell surface receptor uPAR, has a broad capacity to regulate matrix remodeling, which has 
implications for both angiogenesis and cancer cell motility.  Like thrombin and APC, uPA can 
also directly activate intracellular signaling pathways in cancer cells that promote growth and 
motility, albeit by different mechanisms.  In the tumor microenvironment, the interplay of these 
three proteases has the potential to greatly impact cancer cell growth and metastasis.   
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Introduction 
 The serine proteases thrombin, activated protein C (APC), and urokinase-type  
plasminogen activator (uPA) are known for their role in regulating hemostatic and fibrinolytic 
pathways.  Thrombin catalyzes the culminating event in clot formation via cleavage of 
fibrinogen to form fibrin, which polymerizes to form a hemostatic plug (clot).  APC, which is 
activated from its zymogen form protein C (PC) by thrombin bound to thrombomodulin (TM), 
provides a negative feedback signal to prevent excessive clot formation by its proteolytic 
inactivation of factors Va and VIIIa.  uPA, similar to its counterpart tissue plasminogen activator 
(tPA), initiates fibrinolysis by cleaving plasminogen into plasmin, which catalyzes the 
degradation of fibrin to fibrin degradation products.  
More recently, characterization of molecular targets of these proteases outside of 
hemostasis and fibrinolysis has revealed their broad capacity for participating in various 
physiological and pathophysiological processes.  Discovery of the GPCR protease activated-
receptor-1 (PAR-1) has revealed direct cell signaling activated by thrombin and APC through 
cleavage of PAR-1 in multiple cell types.  Outside of its capacity to activate fibrinolysis, uPA is 
capable of initiating proteolytic cascades that drive extracellular matrix remodeling.  All three of 
these serine proteases have been shown to activate or induce growth factors to promote 
angiogenesis, directly promote cell motility, and in some cases act as mitogens.  The diverse, and 
at times convergent, pathways regulated by these coagulation proteases have profound 
implications in cancer.  This review aims to briefly address the potential mechanisms whereby 
these proteases can participate in cancer pathophysiology – notably with regard to cancer cell 
proliferation and motility, angiogenesis, and metastasis.    
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Thrombin 
When a vessel is injured, the extrinsic pathway of blood coagulation is initiated by the exposure 
of tissue factor (TF) to blood.  TF is a transmembrane receptor that is expressed on epithelial 
cells, smooth muscle, and other cell types and is not typically exposed to blood [1,2].  The TF-
factor VIIa complex activates factor X to Xa and factor IX to IXa.  Factor Xa activates 
prothrombin to thrombin [Reviewed in 3, 4].  Thrombin subsequequently catalyzes the cleavage 
of fibrinogen to fibrin and is also capable of activating platelets via cleavage of PAR-1 and PAR-
4 [5].  Many have shown that TF is expressed on tumor-associated endothelial cells [6], stromal 
cells surrounding the tumor [7], and the tumor cells themselves [8].  In this way cancer can 
activate thrombin, which has downstream effects on tumor growth and metastasis mainly 
through the effects of thrombin on its primary target PAR-1.  PAR-1 is capable of activating 
multilple signaling pathways via its documented coupling to multiple G protein families 
[Reviewed in 9].  
Correlations between thrombin activity and cancer development/metastasis.  
 Multiple studies have demonstrated direct linkages between thrombin activity and cancer 
as well as linkages between thrombin activity and the proclivity of cancer to metastasize.  
Thrombin activity is elevated in peripheral blood in patients with glioma [10] as well as multiple 
blood borne myeloproliferative neoplasms [11].   For lung cancer, elevated thrombin activity in 
blood is associated with greater extent of disease in small cell and non-small cell lung cancer as 
well as impaired response to chemotherapy [12].   With regard to metastasis, elevated thrombin 
in the bronchoalveolar fluid of osteosarcoma patients is associated with high risk of developing 
pulmonary metastases [13].   
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In other forms of tumors, expression of PAR-1, the thrombin receptor, has been shown to 
correlate with increased metastasis.  PAR-1 over-expression has been demonstrated in high grade 
breast cancers [14] and melanoma cell lines isolated from metastatic lesions express higher 
levels of PAR-1 than those isolated from lesions that did not metastasize [15].  By contrast, 
immunohistochemial analysis of squamous cell carcinoma of the head and neck showed that 
PAR-1 expression is associated with the induction of differentiation markers and inversely 
correlated with lymph node metastasis [16].    
 
Animal Models linking thrombin to cancer growth and metastasis 
 A few animal models to date have been used to examine linkages between thrombin 
activity and PAR-1 expression to metastasis.  Using ATAP2 and WEDE15, antibodies which 
block PAR-1 cleavage and activation, Shi et al. demonstrated PAR-1 antagonism reduces human 
melanoma metastasis to lung secondary to tail vein injection [17].  Studies utilizing subcutaneous 
injection of breast cancer cells in nude and syngeneic mice demonstrated that treatment with 
hirudin, a thrombin inhibitor, caused a lag in initial growth, induction of central necrosis in the 
primary tumor, and reduced hematological spread and seeding in distant organs [18].  Using the 
TRAMP mouse model of prostate cancer, in which spontaneous prostate cancer develops and 
whose course mimics the human disease, treatment of mice with hirudin led to a reduction in 
spontaneous tumor growth [19].   
 
In vitro studies and proposed mechanisms for association between thrombin and cancer 
pathophysiology  
Cloaking Hypothesis and Dissemination   
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The most direct proposed linkage between thrombin activity and cancer pathophysiology 
is what one may deem the “Cloaking Hypothesis.”  This hypothesis suggests that cancer cells, 
especially those that express tissue factor as an initiator of coagulation, are capable of 
surrounding themselves with a fibrin mesh, thereby preventing immune surveillance and 
destruction by natural killer cells [20].  This concept is supported by the multiple demonstrations 
that thrombin treatment of cancer cells increases their adhesiveness to platelets [21].   
 In addition to its potential to initiate a fibrin “cloak,” thrombin may also mediate cancer 
cell metastasis by enhancing extravasation at distant sites.  Thrombin treatment of tumor cells 
has been demonstrated to increase their adhesiveness to endothelial cells and the subendothelial 
matrix [22].  Furthermore, at concentrations just above physiological levels, thrombin can induce 
barrier disruptive signaling in endothelial cells [23], thereby allowing enhanced extravasation at 
a potential metastatic site.   
 
Cancer cell proliferation and motility 
 Multiple studies have documented the expression of functional PAR-1 in cancer cell lines 
and the capacity of PAR-1 activation to promote cancer cell motility including melanoma [15], 
prostate [24, 25], renal carcinoma [26], breast [27], and osteosarcoma [28], among others. 
Furthermore, downregulation of PAR-1 via siRNA targeting conversely leads to decreased 
motility and invasion through basement membrane extract in melanoma [15] and breast cancer 
cells [29].  Thrombin induced migration has been linked to a variety of signaling pathways.  
Kaufmann et al report that thrombin induced migration of renal carcinoma cells is dependent on 
activation of NFκB, PKA, MAPK, and PKC pathways [30].  PKC activation dependency was 
also demonstrated by Chiang et al in adenocarcinoma cells [31].  A common observation in 
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thrombin induced motility is induction of matrix metalloprotease (MMP) production [32, 33, 28, 
34].  Using osteosarcoma cell lines, Radjabi et al have proposed a mechanism in which 
thrombin-mediated PAR-1 activation leads to upregulation of MMP-9 and β1 integrins, which 
colocalize at the cell surface to mediate invasion through a PI3K dependent pathway [28]. 
In addition to motility and invasion, thrombin and PAR-1 have also been shown to 
directly promote cancer cell proliferation.  Thrombin has been demonstrated to stimulate 
proliferation in glioma [35], gastric [36], and colon [37] cancer cell lines.  In prostate and 
glioblastoma cancer cells, Hu et al further demonstrated that thrombin modulates key regulators 
of cell cycle progression including downregulation of p27Kip1, a universal cyclin-dependent 
kinase inhibitor [38].    While the precise mechanisms underlying thrombin induced cancer cell 
proliferation require further investigation, multiple studies have demonstrated that thrombin 
induced proliferation involves transactivation of the EGFR receptor [39, 36, 37, 26].   
 
Angiogenesis 
 Given the well documented capacity for thrombin to promote both motility and 
proliferation in cancer cells, it is perhaps unsurprising that thrombin can also promote 
angiogenesis – a process dependent upon motility and proliferation of endothelial cells.  Indeed, 
in vitro, thrombin induces tube formation in human umbilical vein endothelial cells (HUVEC) 
[40].  Furthermore, thrombin has also been demonstrated to activate endothelial cells to replicate 
and to produce angiogenic growth factors such as VEGF [41] and angiopoietin-2 [42].  With 
regard to the matrix remodeling that is required for the formation of new vessels, thrombin 
stimulates endothelial cells to produce MMP-1 and MMP-3 [43].  
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Activated Protein C 
The role of activated protein C (APC) in coagulation is to prevent excessive thrombin generation 
at the site of an injury.   Zymogen protein C is localized on endothelial cells by binding to the 
endothelial protein C receptor (EPCR) [44].  Protein C is activated by thrombin bound to the 
endothelium by thrombomodulin (TM) [44, 45].  In the presence of protein S [43], APC prevents 
further thrombin generation by proteolytically inactivating upstream coagulation factors Va and 
VIIIa  [46, 47].   
Interestingly, APC, like its activator thrombin, has been shown to activate PAR-1 in the 
presence of EPCR and modulate cell signaling.  Despite the tight linkage between thrombin 
activity and APC, and the fact that they are capable of activating the same receptor, there is 
relatively little known about linkages between APC and cancer pathophysiology.  However, 
there is emerging evidence that, depending on experimental context, APC can function in a 
fashion parallel or anti-parallel to thrombin.   
Direct effects of APC on motility of cancer cells 
EPCR, whose presence is required for APC activation, has been detected in breast cancer 
biopsies as well as multiple glioma and leukemia cell lines and can functionally activate 
zymogen protein C [48].  In vitro, Kobayashi et al demonstrated APC promotes motility of 
choriocarcinoma and ovarian cancer cells in the presence of the serine protease inhibitor (serpin) 
PAI-1 [49].  Rather than implicate signaling through PAR-1, they suggested the APC bound to 
PAI-1, a serine protease inhibitor that naturally inhibits uPA (reviewed below), thereby 
increasing the capacity of uPA to promote motility.  Alternatively, it has been shown that APC 
promotes motility and invasion of MDA-MB-231 and MDA-MB-435 breast cancer cells by 
mechanisms that are dependent on EPCR and PAR-1 that involves activation of PI3K and 
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MAPK signals [50, 51].  Another group showed with keratinocytes [52] that APC is capable of 
activating pathways that promote proliferation and are anti-apoptotic and should be further 
investigated for its capacity to directly affect cancer cells.   
Pro-angiogenic vs. barrier protective functions of APC 
Much more is known with regard to the effects of APC on endothelial cells than cancer 
cells.  However, depending on one’s perspective on angiogenesis vs. barrier function, APC may 
act positively or negatively with regard to cancer outcomes.  In this way, APC may have effects 
which could positively or negatively impact cancer pathophysiology in different disease stages.   
 
Angiogenesis  
Like thrombin, APC promotes motility and tube formation of endothelial cells [51, 53].  
Furthermore, like thrombin, APC promotes proliferation, increased DNA synthesis, and 
activation of MAPK and PI3K in HUVEC and angiogenesis in mice cornea [53].    In wound 
healing models, APC promotes angiogenesis via increased transcription of MMP-2 in endothelial 
cells and VEGF in fibroblasts [54]. Beyond induction of MMP-2 and VEGF, APC may also 
broadly stimulate angiogenesis through its capacity to promote transcription of the pro-
angiogenic cytokines monocyte chemoattractant protein 1 (MCP-1) and interleukin 8 (IL-8) in 
both endothelial cells and fibroblasts [55].  The studies which indicate APC promotes 
angiogenesis imply APC may promote cancer growth by being pro-angiogenic.  However, in 
contrast, the capacity of APC to promote barrier function would make APC protective against 
tumor dissemination.  There are multiple in vivo studies to date suggesting this function of APC. 
 
Endothelial barrier protective activity 
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APC has an pro-survival effect on endothelial cells [56-58].  This is mediated by both 
direct signaling to endothelial cells and by modulating the production of various cytokines such 
as TNFα to prevent neutrophil mediated killing [59].  More mechanistically, APC has been 
shown to enhance HUVEC barrier integrity in a two chamber system electrical resistance model 
that  is dependent on PAR-1 and activation of S1P pathways involved in processes such as cell 
proliferation, survival and migration [60].  As mentioned previously, thrombin generates barrier 
disruptive signaling in endothelial cells.  Using HAEC, Finigan et al found APC reversed 
thrombin induced barrier disruption, restoring peripheral cortical actin distribution thereby 
restoring barrier function by a S1P dependent mechanism [61].  Supporting a role in barrier 
protective signaling, melanoma cells pretreated with APC exhibited decreased adhesion and 
transmigration through endothelial monolayers [62]. 
The barrier protection functions of APC are documented relative to the use of APC in 
treating severe sepsis; however, how this contributes to cancer pathophysiology has only recently 
been explored.  Mice over-expressing EPCR exhibit reduced lung and liver metastasis secondary 
to tail vein injection [62].  In addition, treatment of mice with APC blocking antibodies 
decreased lung metastasis of melanoma cells, reduced extravasation as a consequence of reduced 
S1P activity, and reduced VE-cadherin expression in melanoma cells [63].  These in vivo studies 
examine hematological spread of injected cancer cells and strongly suggest APC would be 
protective against hematological metastasis.  There are no in vivo studies to date which address 
the effect of APC on primary tumor growth or cancer related angiogenesis. Further studies are 
required to elucidate the effects of APC on primary tumor growth and local metastasis, 
especially in light of the similar capacities of APC and thrombin to modulate tumor cell motility 
and angiogenesis 
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In general, APC and thrombin have been shown to activate similar pathways with regard 
to proliferation and motility in both primary cells such as HUVEC as well as cancer cells.  It is 
intriguing that APC and thrombin have opposite effects on endothelial cell layers given that they 
exert cell signaling functions via cleavage of the same receptor.  Notably thrombin and APC 
activate PAR-1 with different efficiencies.  At low levels, thrombin is barrier protective [23] and 
APC cleaves PAR-1 less efficiently than thrombin and requires a co-receptor.  Differential 
signaling may therefore depend on rate of activation.  It has also been demonstrated that 
thrombin selectively activates RhoA in endothelial cells whereas APC selectively activates Rac.  
This study further demonstrated APC signaling is uniquely dependent on the presence of 
caveolin 1 and induces PAR-1 phosphorylation but not internalization or degradation [64, 65].  
 
Urokinase plasminogen activator 
As related to hemostasis, urokinase plasminogen activator (uPA), similar to tissue plasminogen 
activator (tPA), catalyzes the conversion of plasminogen to plasmin.   Plasmin catalyzes the 
degradation of fibrin, thereby mediating fibrinolysis.  In the extravascular space, binding of uPA 
to its cognate cell surface receptor uPAR, allows for efficient activation of plasminogen in the 
pericellular space [66, 67].  uPA activity at the cell surface is inhibited by the cognate inhibitor 
of uPA, plasminogen activator inhibitor 1 (PAI-1).  PAI-1 forms a 1:1 complex with uPA and 
renders the protease inactive, thereby inhibiting pericellular proteolysis.  uPA-PAI-1 complexes 
are subsequently endocytosed at the cell surface by the low density lipoprotein-like receptor 1 
(LRP-1).  Extensive research has revealed that outside fibrinolysis, uPA and its cell receptor 
uPAR have broad capacity for regulating processes such as matrix remodeling, cancer cell 
motility and growth, as well as angiogenesis.  The effects of thrombin and APC are generally 
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dependent on proteolysis, through PAR-1 cleavage and subsequent activation at the cell surface.  
uPA, by contrast, is capable of both broadly regulating matrix remodeling through protease 
dependent mechanisms as well as regulation of cell growth and motility through both protease-
dependent and protease-independent mechanisms.   
 
Correlations between uPA/uPAR expression and cancer development and metastasis. 
Elevated uPA and or uPAR expression has been documented in diverse forms of cancer 
and in many cases is strongly correlated to poor disease outcomes.  For example, uPA antigen is 
elevated in biopsies ranging from glioblastoma multiforme [68] to colorectal cancer [69].  In 
prostate cancer, elevated uPA antigen is found in peripheral blood [70].  In breast cancer, 
elevated expression of uPA and its PAI-1 [reviewed in 71]  is predictive of lower rates of 
relapse-free survival and overall survival [72].   Elevated uPA antigen in tumor biopsies has also 
been shown to correlate with decreased relapse-free survival in gastric cancer [73] and shorter 
overall survival in colorectal cancer [74].  With regard to characterizing the aggressiveness of 
particular cancers, uPAR amplification  is associated with invasive capacity of pancreatic 
adenocarcinoma [75], uPA elevation is correlated with bone metastasis in renal cancer [76], and 
uPA is a strong predictor of distant metastatic disease and shorter overall survival in colorectal 
cancer [77]. 
 
Mouse models relating uPA and cancer growth and metastasis 
 Mouse models utilizing a variety of tumor cell lines have demonstrated a strong 
etiological linkage between uPA and uPAR expression and cancer progression.  In an orthotopic 
model of breast cancer, Kunigal et al. demonstrated that injection of uPAR targeted RNAi 
17 
 
constructs regressed breast tumors in mice [78].  Similarly, in a prostate cancer model, it has 
been demonstrated that injection of uPA and uPAR shRNA constructs into established tumors 
inhibits tumor growth and survival [79]. In glioblastoma models, uPA and uPAR antisense 
constructs can similarly reduce tumor growth lead to regression of established tumors [80, 81].  
With regard to metastasis, Margheri et al demonstrated uPAshRNA constructs inhibit prostate 
cancer bone metastasis [82] and D-Alessio [83] et al demonstrated uPAR anti-sense treatment 
reduces melanoma metastasis to lung.  In a finding that is promising with regard to the 
development of treatment strategies, treatment of mice bearing orthotopic pancreatic carcinoma 
cells with an anti-uPAR monoclonal antibody reduced tumor growth and retroperitoneal and 
liver metastasis [84].  Taking a different approach to address the contributions of tumor produced 
vs. host produced uPA, Gutierrez et al demonstrated diminished growth of fibrosarcoma cells in 
uPA null mice [85].   
   
In vitro characterization of the effects of uPA/uPAR in cancer pathophysiology 
There is a large body of research demonstrating the broad signaling capacity of uPAR.  A 
GPI-anchored receptor, uPAR has been demonstrated to co-localize with a large number of co-
receptors, including multiple integrin subunits and EGFR among others.  This literature has been 
comprehensively reviewed [see 86, 87].  Here, we focus more narrowly on mechanisms which 
relate more directly to uPA.   
 
Cancer cell motility 
 Put most simply, association of uPA with uPAR allows for efficient cleavage of 
plasminogen to plasmin in the pericellular space [66].  This initiates a proteolytic cascade that 
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ultimately leads to degradation of extracellular matrix (ECM) proteins surrounding a cancer cell.  
More specifically, plasmin can directly proteolyze ECM proteins fibronectin and vitronectin 
[88].  Plasmin also indirectly degrades matrix components via the activation of latent matrix 
metalloproteases (MMPs), including MMP-1 [89], MMP-2 [90], MMP-3 [91], MMP-11, and 
MMP-12 [92].  The initiation of this proteolytic cascade is inhibited by PAI-1.  Collectively, as a 
consequence of activating a broad proteolytic cascade, uPA acts as a driver of matrix remodeling 
which is a key factor in cancer motility.  Figure 2.1 diagrams the interplay of uPA and PAI-1 in 
the regulation of matrix remodeling.   
uPA can also act as a direct motogenic factor independent of its capacity for plasmin 
generation by activating cell signaling.  In MCF7 breast cancer and HT1080 fibrosarcoma cells, 
uPA stimulates migration via activation of the Ras, MEK, ERK signaling axis [93].  In LNCap 
prostate cancer cells transfected with uPAR, ligation with uPA or the amino terminal fragment of 
uPA (ATF), which lacks proteolytic capacity, induced motility with activation of a number of 
intracellular mediators of migration including FAK and p130Cas [94].  From a different 
perspective, it has also been demonstrated that the metastatic MCF10CA1 breast cancer cell line 
derived from normal epithelial MCF10A cells are more motile toward EGF as a consequence of 
both uPA activity and production [95]. 
 
Proliferation and Apoptosis 
 In addition to its capacity to regulate motility, uPA has also been demonstrated to affect 
both the proliferation and sensitivity to apoptosis of cancer cells themselves.  uPA activates ERK 
signaling – a key modulator of proliferation in multiple cell types [96, 97].  Further, the ATF 
fragment of uPA (which lacks proteolytic capacity) stimulates proliferation in ovarian [98] and  
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Figure 2.1. The Plasminogen Activator System at the cell surface.   The catalytic activity of uPA is 
enhanced when bound to the cell surface by uPAR.  uPA cleaves the zymogen plasminogen to its active form 
plasmin.  Plasmin can subsequently activate MMPs in the microenvironment, thus contributing to invasion and 
metastasis via degradation of the ECM and basement membrane.  When uPA is neutralized via covalent linkage to 
PAI-1, the trimeric uPAR/uPA/PAI-1 complex  is bound by LRP and internalized.   
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osteosarcoma cell lines [99].   Other studies have suggested that uPA promotes anti-apoptotic 
signaling in cancer cell lines.  Ma et al found that inhibition of uPA binding to uPAR in MDA-
MB-231 breast cancer cells protected the cells from apoptosis, which they attributed to decreased 
ERK activity secondary to antibody inhibition.  Glioma cells with reduced uPAR exhibit 
increased sensitivity to TRAIL induced apoptosis.  In glioblastoma cells, Chandrasekar et al. 
showed that treatment of cells with uPA antisense correlated with reduced PI3K activity and 
survival [100].  
 
Angiogenesis 
While there is a larger body of experimental evidence linking uPA to cell  
motility, proliferation, and survival of cancer cells themselves, its array of biological activities 
has strong ties to angiogenesis.  Like thrombin and APC, uPA has been shown to enhance 
invasive capacity of endothelial cells through matrix proteins [101] and promote tube formation 
[102].  Furthmore, plasmin also stimulates endothelial cell migration [103].   
 Both uPA and plasmin have been implicated in catalyzing the release of matrix bound 
growth factors or activation of pro-angiogenic factors.  uPA and plasmin can both directly 
mediate activation of VEGF [104]. Plasmin can also catalyze the release of matrix bound VEGF 
[105].  In addition to VEGF, plasmin can also indirectly induce the release of ECM bound bFGF, 
another pro-angiogenic factor, via MMP activation [106].  Interestingly, stimulation of 
endothelial cells with VEGF results in the up-regulation of uPA, creating the potential for a 
feedback loop [107].   
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Conclusions 
 Examination of the coagulation proteases thrombin, APC, and uPA in the context of 
cancer physiology reveals the complex contribution of these factors to a broad array of 
mechanisms ranging from motility and matrix remodeling to proliferation and apoptosis.  The 
well documented  interplay of these factors in regulating hemostasis and fibrinolysis calls for 
continued research into how they may interact to regulate processes involved in cancer.  Indeed, 
studies with endothelial cells reveal thrombin mediated activation of MMP-2 is dependent on the 
presence of TM and the generation of APC, suggesting activities once thought mediated by 
thrombin or APC alone may require both proteases [108].  Furthermore, it has been recently 
shown that treatment of mouse breast cancer cells with thrombin can induce bolus release of uPA 
from intracellular stores [109].  Moving forward, it will be important to determine if coordinate 
activities of thrombin, APC, and uPA contribute to cancer growth and metastasis.   
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Abstract 
 Activated protein C (APC), an anticoagulant serine protease, has been shown to have 
non-hemostatic functions related to inflammation, cell survival, and cell migration. In this study 
we investigate the mechanism by which APC promotes angiogenesis and breast cancer invasion 
using ex vivo and in vitro methods.  When proteolytically active, APC promotes cell 
motility/invasion and tube formation of endothelial cells.  Ex vivo aortic ring assays verify the 
role of APC in promoting angiogenesis, which was determined to be dependent on EGFR and 
MMP activation.  Given the capacity of APC to promote angiogenesis and the importance of this 
process in cancer pathology, we investigated whether the mechanisms by which APC promotes 
angiogenesis can also promote motility and invasion in the MDA-MB-231 breast cancer cell line.  
Our results indicate that, extracellularly, APC engages EPCR, PAR-1, and EGFR in order to 
increase the invasiveness of MDA-MB-231 breast cancer cells. APC activation of matrix 
metalloprotease (MMP) -2 and/or -9 is necessary but not sufficient to increase invasion, and 
APC does not utilize the endogenous plasminogen activation system to increase invasion.  
Intracellularly, APC activates ERK, Akt, and NFκB, but not the JNK pathway to promote breast 
cancer migration.  Similar to the hemostatic protease thrombin, APC has the ability to enhance 
both endothelial cell motility/angiogenesis and breast cancer cell migration.   
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Introduction 
Activated protein C (APC), a liver-derived serine protease [1] has known functions in 
vivo as an anticoagulant.  Zymogen protein C (PC) is localized to the endothelium by binding to 
endothelial cell protein C receptor (EPCR) [2]. Thrombin bound to the endothelial cell surface 
by thrombomodulin (TM) [2,3], cleaves PC into its active form.  Along the periphery of the clot, 
APC proteolytically inactivates factors Va and VIIIa [4,5] in the presence of protein S (PS) [6,7].  
In humans, severe thrombophilia occurs with deficiencies in PC or PS and with a mutation in 
factor Va that prevents its inactivation by APC, known as Factor V Leiden [8].  Recently, in the 
Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) 
Study, patients diagnosed with sepsis and acute organ dysfunction were treated with recombinant 
human APC, resulting in a mortality reduction of 19.4% [9].                                                                      
APC has a role in regulating migration of various cell types.  Kobayashi, et al. [10] 
originally reported APC promotes invasion of ovarian cancer and choriocarcinoma cells only in 
the presence of the serine protease inhibitor (serpin) plasminogen activator inhibitor-1 (PAI-1). 
They suggest APC forms a stable complex with PAI-1, thereby removing a potent inhibitor of 
urokinase plasminogen activator (uPA) from the system [10].  uPA directly activates matrix 
metalloprotease (MMP)-2 and uPA can also regulate MMP-9 expression [11-13], both of which 
are zinc-dependent proteases that degrade the ECM.  Plasmin, which is activated directly by 
uPA,  can also activate both MMP-9 [14] and MMP-2 [15].  Previously, APC has been shown to 
activate MMP-2 from an intermediate to a fully active protease [16-19].  In vitro cell culture 
assays with keratinocytes have shown that APC promotes cell migration by increasing both the 
expression and activation of MMP-2 [19]. In vivo, APC promotes angiogenesis and wound 
healing by reducing inflammation, increasing VEGF expression, and increasing MMP-2 [17]. 
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Beyond its potential for manipulating the activation of MMP’s, APC has also been 
implicated in intracellular signal transduction pathways, which alter proliferation and migration. 
APC has been shown to increase endothelial cell proliferation and in vivo angiogenesis in a 
concentration dependent manner through activation of the mitogen activated protein kinase 
(MAPK), phosphatidylinositol-3 kinase (PI3K), and endothelial nitric oxide synthase (eNOS) 
pathways [20].  It has also been shown that APC, in the presence of caveolin-1, activates Rac1 
through PAR-1 to promote protective barrier signaling in immortalized HUVEC [21].  There is 
relatively limited data on APC induced signal transduction in cell types outside of endothelial 
cells.  However, it has been shown that in epidermal keratinocytes, APC can stimulate the 
MAPK pathway via transactivation of the epidermal growth factor receptor (EGFR) [22].   
Our primary objectives in this study were to (1) confirm the role of APC in promoting 
angiogenesis using both in vitro and ex vivo models; (2) explore the role of MMP and EGFR 
activation in APC stimulated angiogenesis; and (3) examine the mechanism that accounts for our 
previous finding that APC can promote motility in MDA-MB-231 breast cancer cells [23].   The 
results described here provide evidence that MMP and EGFR activation are necessary for APC 
induced angiogenesis.  Furthermore, the results indicate that APC promotes breast cancer cell 
motility and invasion through pathways similar to those previously reported for endothelial cells 
and keratinocytes, but different from the mechanism reported for other cancer cells.  Specifically, 
this mechanism involves binding to EPCR, activation of both PAR-1 and EGFR to promote 
intracellular signaling through MAPK and PI3K pathways, and extracellular interactions with 
MMP-2 and -9 to support ECM degradation.   
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Material and Methods 
Cell Culture.  Human umbilical vein endothelial cells (HUVEC), obtained from 
Cambrex, were grown according to manufacturer’s specifications. Cells were grown in 
endothelial cell basal media with 2% fetal bovine serum (FBS), bovine brain extract (BBE) with 
heparin, GA-1000, human epidermal growth factor (hEGF), and hydrocortisone (Cambrex). 
Assays were performed using the MDA-MB-231 breast cancer cell line obtained from the 
University of North Carolina – Chapel Hill Tissue Culture Facility. These cells were maintained 
in Minimum Essential Media (MEM; Gibco) with 10% FBS (Sigma), 1% sodium pyruvate 
(Gibco), and 1% antibiotic/antimycotic (Gibco). All cells were cultured in an incubator at 37oC, 
5% CO2. 
Immunofluorescence.  In the murine ex vivo aortic ring assays, after 5 days in culture, 
aortic sections were fixed in 4% paraformaldehyde in 1X PBS for 30 minutes on ice. After 2 
washes in 1X PBS, the sections were permeabilized with 0.5% Triton X-100 in 1X PBS for 15 
minutes on ice.  To block any reactive aldehyde groups, the sections were treated with 0.2 M 
glycine for 20 minutes on ice and washed. Each section was blocked overnight in 10% goat 
serum in 1X PBS, 1% BSA at 4oC.  The following day each section was washed in 1X PBS and 
then treated with a rabbit polyclonal anti-von Willebrand factor (vWF) antibody (1:50 in 1X 
PBS, 1% BSA; Dako) or normal rabbit serum, overnight at 4oC. The next day, each aortic section 
was washed 5 times with 1X PBS, 1% BSA, then allowed to sit in this wash solution overnight at 
4oC. Each section was treated with goat F(ab´)2 anti-rabbit IgG conjugated to Lissamine 
Rhodamine-B (1:50 in 1X PBS, 1% BSA; BioSource International), covered, and stored 
overnight at 4oC. Each aortic section was washed 5 times with 1X PBS and stored in 1X PBS, 
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covered at 4oC, until photographs could be taken with the Olympus IMT2 Inverted Flourescence 
Microscopy using a TRITC filter. 
 For experiments with MDA-MB-231 cells, cells grown to form a confluent monolayer in 
2-chambered slides (Lab Tek II by Nunc) were fixed and stained as previously described [23] 
without permeabilization. Cells were blocked in 10% goat serum in 1X PBS, 1% BSA for 30 
minutes and then treated with mouse EGFR antibody (Upstate) or serum mouse IgG (5 µg/mL; 
Sigma) for 1 h. After multiple washes in 1X PBS, 1% BSA, cells were treated with sheep anti-
mouse IgG F(ab´)2 fragment-R-phycoerythrin antibody (1:20; in 1X PBS, 1% BSA) for 1 hour. 
Cells were then washed multiple times in 1X PBS and stored in 1X PBS at 4oC. Photographs 
were taken with an Olympus DP70 Microscope Digital Camera with DP70-BSW Software using 
an Olympus BX51WI fluorescent microscope with a TRITC filter. Photographs were taken at a 
200X magnification with the same exposure time. 
 Tube Formation Assay.  In a 24-well plate, wells were coated with Growth Factor-
Reduced Matrigel (BD Biosciences) and incubated for 1 h at 37oC. 80,000 HUVEC/well were 
plated with increasing concentrations of APC (0-10 µg/mL; Xigris®; Eli Lilly and Co.), PC (10 
µg/mL Hematologic Technology), APC-DEGR (10 µg/mL Hematologic Technology), or VEGF 
(100 ng/mL R&D Systems) and incubated at 37oC for 18 h. Photographs were taken at 6, 12, and 
18 h using Adobe Photoshop and a Kodak DC290 Digital Camera mounted on an inverted 
microscope. The number of tube-like structures (defined at a structure no more than 3 cells wide 
with junction points on each end) were counted in 4-100X views.  
 Murine Ex Vivo Aortic Ring Assay.  Wildtype C57BL/6 (Charles River) mice were 
maintained by the Veterinary Staff of the University of North Carolina at Chapel Hill 
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Department of Laboratory Animal Medicine and all mouse protocols were reviewed and 
approved by the University’s Institutional Animal Care and Use Committee (IACUC).  
Based on previous work [24], male and female mice, at varying ages, were anesthetized 
with 1.25% tribromethanol (0.2 mL/10g) and monitored by toe reflex response and respiratory 
rate. Once properly anesthetized, an incision was made midline and the organs were removed to 
expose the aorta from the heart to the renal arterial branch point. The aorta was dissected from 
the heart to the split for the renal arteries. The dissected aorta were placed in a 100 mm dish 
containing Dulbecco’s Modified Eagle Media (DMEM; Gibco) with 1% antibiotic/antimycotic 
(Gibco) and cleaned of connective tissue and fat. Cleaned aortas were then sectioned into 1-2 
mm pieces and placed into a new 100 mm dish containing DMEM with 1% 
antibiotic/antimycotic and allowed to incubate for approximately 1 h at 37oC, 5% CO2 until 
implantation.  In a 48-well plate, 200 µL of Growth Factor-Reduced Matrigel was plated in each 
well and placed in an incubator at 37oC, 5% CO2 for 10 minutes. One aortic section per well was 
placed on top of the gelatinized Matrigel, covered with an additional 200 µL of Growth Factor-
Reduced Matrigel, and incubated for 10 minutes. 200 µL of endothelial basal media with 2% 
FBS, BBE with heparin, GA-1000, hEGF, and hydrocortisone (Cambrex) was added to each well 
with either no additional treatment (negative control), 100 ng/mL VEGF (positive control), or 
increasing concentrations of APC (0-10 µg/mL).  To eliminate any effects of thrombin on sprout 
formation, 50 nM of hirudin was added to the aortic sections with or without APC (10 µg/mL). 
To determine if the active form of APC was needed to increase sprout formation, aortic sections 
were also treated with PC (10 µg/mL) with or without hirudin (50 nM) or APC-DEGR (10 
µg/mL). In studies looking at EGFR, PI3K, and MMPs, pharmacological inhibitors, AG 1478 
(10 µM;Biomol) [25], LY 294002 (10 µg/mL; Biomol) [26], and GM 6001 (10 µg/mL;Biomol) 
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[27], respectively, were added to the aortic sections 30 minutes prior to the addition of APC (10 
µg/mL). Every 24 h for 5 days, media from each well was removed and replaced with fresh 
conditioned media. On days 3-5, the number of sprouts extending form the periphery of the 
aortic sections was counted and digital photographs were taken using Adobe Photoshop and a 
Kodak DC290 Digital Camera mounted on an inverted microscope. 
Western Blots.  25 µg total protein from cell lysates created in complete RIPA buffer 
were run on 12% SDS-PAGE gels and transferred onto PVDF (Millipore). Cell lysates were 
probed for P-ERK1/2 (Santa Cruz Biotechnology), total ERK2 (Santa Cruz Biotechnology), P-
Akt (Cell Signaling), total Akt (Cell Signaling), P-c JUN (Cell Signaling), total c JUN (Cell 
Signaling), IκB-α (Cell Signaling), MMP-2/9 (Chemicon), tubulin (Sigma), and actin (Santa 
Cruz Biotechnology).  
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) Assays Using 
Epidermal Growth Factor.  MDA-MB-231 cell viability was measured using a MTT assay. 
10,000 cells/well were plated in a 96-well plate, incubated overnight at 37oC, 5% CO2. Cells 
were treated with SFM containing 1% sodium pyruvate, 1% antibiotic/antimycotic with mouse 
EGFR antibody or mouse serum IgG for 15 min followed by the addition of recombinant hEGF 
(1nM final concentration; Invitrogen). After a 48 h incubation, cells were treated with SFM with 
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (0.5 mg/mL; Sigma) 
for 2 h. DMSO was added to each well to dissolve the formazan crystals formed by living cells 
for 15 min at 37oC, 5% CO2. The absorbance of each well was read at 560 nm.  
 Transwell Invasion and Chemotaxis Assays.  Migration was evaluated as previously 
described using the transwell invasion and chemotaxis assays [23, 28, 29]. For endothelial cells, 
the chemotactic agent, 1 ng/mL VEGF (R&D Systems) in culture media was added to the well. 
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50,000 cells/insert were treated with increasing concentrations of APC (0-10 µg/mL; Xigris®; 
Eli Lilly and Co.) in culture media and added to the insert. Endothelial cell invasion and 
chemtoxis assays were both incubated for 24 hr.  MDA-MB-231 cells, also plated at 50,000 
cells/insert, migrated towards 10% FBS (the chemotactic agent) containing media. Chemotaxis 
assays for the breast cancer cells were incubated for 12 h, while the invasion assays were 
incubated for 24 h. All experiments were done at 37oC, 5% CO2. Blocking antibodies used to 
study receptors potentially bound by APC were plated with the cells and allowed to incubate at 
room temperature for 15 min prior to the addition of APC. These antibodies include mouse 
EPCR antibody (JNK 1494; provided by Dr. Charles T. Esmon, OMRF, Oklahoma, OK), mouse 
PAR-1 antibodies (atap2 and wede15; Zymed and Immunotech, respectively), mouse EGFR 
antibody (Upstate), and mouse serum IgG (Sigma). Blocking antibodies used to study the role of 
the plasminogen activation system, including goat PAI-1 antibody (American Diagnostica), 
mouse uPA antibody (American Diagnostica), and serum mouse or goat IgG (Sigma), were 
plated with the cells and allowed to incubate at room temperature for 1 h prior to the addition of 
APC. Amiloride, an inhibitor of uPA, was also preincubated for 1h with the cells. 
Pharmacological inhibitors that block specific signaling pathways were plated with the cells and 
allowed to preincubate at room temperature for 1 h. These compounds include PD 98059 
(Biomol), LY 294002 (Biomol), and SP 600125 (Biomol). Finally, inhibitors for MMPs, GM 
6001 (Biomol) and SB-3CT (Biomol) were plated with the cells and preincubated for 15 min 
prior to the addition of APC. To determine if selective inhibitors of MMPs were affecting APC 
activity levels, conditioned media from the transwell assays were tested for APC activity using 
an APC-specific chromogenic substrate (final concentration of 0.15 mM; Centerchem) as 
previously described [23].  
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 Quantitative PCR.  Serum starved MDA-MB-231 cells at ~85% confluence were serum 
starved for 24 h, then treated with SFM containing increasing concentrations of APC (0, 100 
ng/ml, 1 μg/ml, 10 μg/ml). After isolation through Trizol (Invitrogen), RNA was reverse 
transcribed using M-MLV reverse transcriptase (Invitrogen). Quantitative real-time PCR was 
performed using SYBR Green Dye (Applied Biosystems) and the following protocol: 5 minute 
initial denaturation step at 95°C, followed by 40 cycles of 95°C for 20-s, 55°C for 1 min, and 
68°C for 30-s. Using β-actin as a loading control, results were interpreted by the relative quantity 
method (ΔΔCt) as described [30].  Primer sequences were: MMP-2 sense 5’-
ATAACCTGGATGCCGTCGT-3’, MMP-2 anti-sense 5’-AGGCACCCTTGAAGAAGTAGC-
3’, MMP-9 sense 5’-CGGTGATTGACGACGCCTTT-3’, MMP-9 anti-sense 5’-
ACCAAACTGGATGACGATGTCTG-3’, β-actin sense 5’-ATCATGTTTGAGACCTTCAA-3’, 
and β-actin anti-sense 5’-CATCTCTTGCTCGAAGTCCA-3’. 
 Statistical Analysis.  For each transwell experiment, conditions were done in duplicate or 
triplicate and averaged. Averages of each condition were compared to No Treatment, APC alone, 
or blocking antibody/inhibitor alone. Experiments were repeated as indicated in the figure 
legends and averaged together. Results show the percentages compared to No Treatment, which 
is set to 100%. Statistical analysis was performed on each comparison – to No Treatment, APC, 
or blocking antibody/inhibitor – using a one sample T-test with a normal distribution, a 
theoretical mean of 100, and significance of p < 0.05. For quantitative real time PCR, ΔΔCt 
values were averaged from three independent experiments and compared to a theoretical mean of 
1, also using a one sample T-test, p<0.05.   
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Results 
APC Promotes Endothelial Cell Motility and Angiogenesis.  Given the previous reports in 
vivo that APC may directly promote angiogenesis, we were interested in closely examining this 
phenomenon using an in vitro and ex vivo models in parallel.  For the in vitro model, HUVEC 
were treated with increasing concentrations of APC in the transwell chemotaxis and invasion 
assays, with VEGF (1 ng/mL) as the chemotactic agent. As seen in Figure 3.1A, APC optimally 
promoted invasion at 0.1 µg/mL and chemotaxis at 0.5 µg/mL.  Notably, this APC-promoted 
increase in invasion and chemotaxis occurs at concentrations that are below the physiological 
level of PC found in plasma (~4 µg/mL). The highest concentration of APC (10 µg/mL) used in 
this assay actually reduced both invasion and chemotaxis of HUVEC compared to No Treatment. 
These results suggest that, in these experimental conditions, HUVEC invasion and chemotaxis 
are increased at a physiologically relevant concentration of APC, but are inhibited at much 
higher levels.  
HUVEC plated onto growth factor-reduced Matrigel will form a network of tube-like 
structures, defined as 1-3 cells wide with junction points at both ends (as seen in Figure 3.1B, No 
Treatment). Upon the addition of a pro-angiogenic factor, VEGF, HUVEC will form an 
increased number of stable tube-like structures (Figure 3.1B, VEGF treatment). As with the 
transwell assays, treatment with increasing concentrations of APC (0-10 µg/mL) increases the 
formation of tube-like structures by 130% at an optimal concentration (1 µg/mL) and at an 
optimal timepoint (12 h) (Figure 3.1C), similar to the effects of VEGF (data not shown).  
 To determine if the effects of APC on tube formation are due to its proteolytic activity, 
HUVEC were also treated with 2 inactive forms of APC, the zymogen PC (1 µg/mL) and the 
chemically inactive protease, APC-DEGR (1 µg/mL). At 12 h, only the active protease is able to 
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significantly increase the formation of tube-like structures by 135% compared to No Treatment 
(Figure 3.1B and C). These results suggest that APC must proteolytically cleave another protease 
or receptors in order to increase the formation of tube-like structures. 
 For the ex vivo model we utilized the murine aortic ring assay.  In this assay, murine 
aortic sections produce sprouts composed of endothelial cells along the periphery of the vessel 
that will lengthen and branch over time. Upon treatment with a pro-angiogenic factor, such as 
VEGF, there will be an increase in the number of endothelial cell sprouts, the length of the 
sprouts, and their ability to survive in culture. As seen in Figure 3.1D, increasing concentrations 
of APC (0-10 µg/mL) increased sprout formation around each section compared to No 
Treatment. Only the highest concentration of APC (10 µg/mL) was able to significantly increase 
the amount (300-400% compared to No Treatment) of sprouts earlier (Day 3) than VEGF (Day 
4). Immunofluorescence staining for vWF, an endothelial cell-specific marker, was done to 
verify that the cells responding to APC treatment were in fact endothelial cells. As seen in Figure 
3.1E, both VEGF and APC were able to increase sprout formation of vWF-positive endothelial 
cells. Therefore, APC increased the formation of endothelial cell sprouts on murine aortic rings 
similar to the pro-angiogenic factor, VEGF. 
 To determine if the effects shown with APC are specific for this protease and not another 
serine protease, thrombin, aortic sections were also treated with hirudin (50 nM), a potent and 
specific inhibitor of thrombin that has been previously shown to inhibit thrombin-promoted cell 
migration [23]. As seen in Figure 3.1F, at day 4, APC increases sprout formation 300-400% 
compared to No Treatment, in the presence and absence of hirudin. The effects of hirudin alone 
are not significant. Further, PC, PC/hirudin, and APC-DEGR did not significantly increase 
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sprout formation over No Treatment (Figure 3.1F). Therefore, APC promotes endothelial sprout 
formation, independent of any thrombin present in this assay. 
 APC promotes angiogenesis through MMP and EGFR activation.  Having shown APC 
promotes angiogenesis in both our in vitro and ex vivo models, we examined whether the 
response is due to activation of MMP and EGFR, as it has been reported both are involved in 
APC mediated motility and proliferation in keratinocytes [19].  To determine if MMPs are 
important in APC-promoted angiogenesis, the general MMP inhibitor, GM 6001, was used in the 
ex vivo murine aortic ring assay. Compared to No Treatment, there was no effect of GM 6001 on 
sprout formation at day 4 (Figure 3.2A).  APC alone increases sprout formation 400% compared 
to No Treatment. When the aortic sections were treated with APC and GM 6001, there is no 
longer an increase over No Treatment as seen with APC alone, suggesting GM 6001 blocks the 
effect of APC on endothelial cell sprout formation (Figure 3.2A). Sprouts that form around the 
periphery of the aortic section treated with GM 6001 and APC are neither as numerous, nor as 
long as the ones that form with APC treatment alone.  Taken together, these results imply that 
APC promotes angiogenesis through MMPs. 
To determine if EGFR activation is involved in APC promoted angiogenesis, murine 
aortic rings were treated with a chemical inhibitor, AG 1478, that blocks ligand binding to 
EGFR. As seen in Figure 3.2B, at day 4, AG 1478 alone reduces the formation of sprouts 
because of the importance of this receptor in angiogenesis. If EGFR is not important to the 
mechanism utilized by APC to increase endothelial cell sprout formation, then APC treatment 
with the inhibitor would be expected to have increased sprout formation relative to inhibitor 
treatment alone.   However, in the presence of AG 1478, APC is unable to increase endothelial 
cell sprout  
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Figure 3.1: APC promotes HUVEC invasion, chemotaxis, tube formation and murine 
aortic ring sprouting. (A) HUVEC were treated with increasing concentrations of APC (0-10 μg/mL) for 24 h, 
using 1 ng/mL VEGF as the chemotactic agent. Black bars are transwell invasion results and the white bars are 
chemotaxis results. (B) Representative photographs of HUVEC plated onto Growth Factor-Reduced Matrigel and 
treated with APC (1 μg/mL), PC (1 μg/mL), APC-DEGR (1 μg/mL), or VEGF (100 ng/mL; positive control) for 12 
h. (C) The number of tube-like structures (defined as 3 cells wide or less with junction points on both ends) were 
quantified at the 12 h time point. All graphs represent the average of 3 separate experiments.  
* p<0.05 compared to No Treatment.  (D) Murine aortic rings were treated with increasing concentrations of APC 
(1-10 μg/mL) or VEGF (100 nM) for 5 days. On days 3-5, the number of sprouts projecting from the periphery of 
the aortic sections was counted. Graph represents the average of 4 separate experiments. * p<0.05, ** p<0.01 
compared to No Treatment. (E) Representative immunofluorescence staining of aortic rings for vWF. (F) Murine 
aortic rings were treated with APC (10 μg/mL) ± hirudin (50 nM), PC (10 μg/mL) ± hirudin (50 nM), APC-DEGR 
(10 μg/mL), or VEGF (100 nM) for 5 days. Graph represents the average of 2-3 separate experiments from data 
collected on day 4. * p<0.05, ** p<0.01 compared to No Treatment. 
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formation relative to the number of sprouts with AG 1478 alone.  Therefore, EGFR is involved 
in the mechanism utilized by APC to increase angiogenesis. 
APC Promotes MDA-MB-231 Breast Cancer Invasion through EPCR and PAR-1.  It has 
been well documented that APC’s ability to promote angiogenesis and alter signaling is 
dependent on binding to cell surface receptors EPCR and PAR-1.  Previously, we showed that 
APC binds to both EPCR and PAR-1 to increase chemotaxis of the MDA-MB-231 breast cancer 
cell line [23].  To further examine the role of these receptors in the overall motility of breast 
cancer cells, we studied the effects of blocking EPCR and PAR-1 in the transwell invasion assay. 
Addition of a blocking antibody to EPCR abrogated the effects of APC on invasion compared to 
APC treatment alone (Figure 3.3A). The PAR-1 blocking antibodies wede15 and atap2 also 
hindered the effects of APC, reducing the level of invasion back to No Treatment (Figure 3.3B).   
 APC Promotes MDA-MB-231 Breast Cancer Chemotaxis through MAPK and PI3K/Akt 
Activation.  Based on previous work that suggested APC is capable of activating the MAPK and 
PI3K/Akt pathways in other cell types, we investigated whether APC can activate these 
pathways in the MDA-MB-231 cells and the impact of these pathways on invasion.  First, cells 
were treated with increasing concentrations of APC.  As shown in Figure 3.4A, at all 
concentrations of APC used, APC activated PI3K as evidenced by increased phosphorylation of 
Akt.  Furthermore, MAPK activity increased in a dose dependent response to APC as evidence 
by increased phosphorylation of ERK1/2.  We further studied the MDA-MB-231 cells using the 
transwell assays to determine if PI3K and MAPK activity had an impact on APC-promoted cell 
chemotaxis (Figure 3.4B).  LY 294002 was used to inhibit PI3K activity and reduce 
phosphorylation of Akt.  LY 294002 completely reduced P-Akt levels (Figure 3.4C) at 50 µM 
without affecting cell viability.  In the transwell chemotaxis assay, LY 294002 caused a loss of  
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Figure 3.2. APC promotes sprout formation of murine aortic rings through MMPs and 
EGFR. Murine aortic rings were pretreated on day 1 with 10 µM of GM 6001 (A) or AG 1478 (B) for 30 minutes 
prior to the addition of APC (10 µg/mL).  Graphs represent the average of 2 separate experiments from data 
collected on day 4.  
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Figure 3.3. APC promotes invasion of the MDA-MB-231 cells by binding to EPCR and 
PAR-1. (A) Cells were pretreated with 4 μg/mL EPCR antibody (JNK 1494) or control mouse serum IgG for 15 
minutes prior to the addition of 10 μg/mL APC. (B) In a separate experiment, cells were pretreated with 10 μg/mL 
atap 2 and 20 μg/mL wede15 (PAR-1 blocking antibodies) or control mouse serum IgG for 15 minutes prior to the 
addition of 10 μg/mL APC. Cells invaded and migrated toward 10% FBS containing media for 24 h. The graphs 
represent the average of 8 separate experiments for both (A) and (B); * p<0.05, ** p<0.01 compared to No 
Treatment; a p< 0.05, aa p<0.01 compared to APC treatment; b p<0.05 compared to mIgG treatment. 
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chemotaxis (Figure 3.4B), as expected since this is an important signaling pathway for cell 
migration.  If this pathway was not activated by APC, we would expect that combined APC and 
LY 294002 treatment would be increased over LY 294002 alone.  However, APC and LY 
294002 treatment was the same as LY 294002 treatment alone (Figure 3.4B), indicating that 
APC promotes cell migration through a PI3K dependent pathway.  
 The PD 98059 compound was used to inhibit MEK1/2 phosphorylation of ERK1/2 
(Figure 3.4E). The 20 µM concentration was used in the transwell assay as it did not inhibit cell 
survival as seen with higher concentrations. Because the MAPK pathway is an important 
signaling pathway for cell migration, treatment with the PD 98059 compound alone reduced 
chemotaxis (Figure 3.4D). Combined APC and PD 98059 treatment was reduced to the same 
level as PD 98059 treatment alone, suggesting that APC promoted cell migration also depends 
on MAPK activity. 
 Notably, chemotaxis assays were also performed using a c JUN inhibitor, SP 600125, 
which inhibits JNK phosphorylation.  Despite the documented links between the JNK pathway 
and EGFR activation [31] and PAR-1 activation [32], treatment with SP 600125 did not inhibit 
APC induced chemotaxis (data not shown), suggesting that the JNK pathway is not involved in 
APC mediated motility.   
 APC Promotes MDA-MB-231 Breast Cancer Motility through EGFR Activation.  Having 
established that EGFR activation is involved in the ability of APC to promote chemotaxis and 
angiogenesis in endothelial cells, we investigated whether EGFR activation is also involved in 
the chemotaxis and invasion of MDA-MB-231 breast cancer cells in response to APC. We 
verified through immunofluorescence the expression of EGFR on the cell surface (Figure 3.5A). 
To confirm this receptor was functional, MDA-MB-231 cells were treated with EGF and cellular  
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 Figure 3.4. APC promotes chemotaxis of MDA-MB-231 cells by activating both the PI3K 
and MAPK pathways.  (A) Cells were treated with increasing concentrations of APC (0, 0.1, 1, and 10μg/ml) 
for 24 h and cell lysates were immunoblotted for phosphorylated and total Akt, as well as phophorylated ERK1/2 
and  total  ERK2.  Additionally, cells were treated with increasing concentrations of (C) LY294002 (0-50 μM) and 
(E) PD98059 (0-50 μM), or (C and E) DMSO for 12 h to determine the optimal concentration of each inhibitor to be 
used in the transwell assay.  Cells lysates were probed for phosphorylated and total Akt (C), phosphorylated ERK1/2 
and ERK 2 (E), tubulin (C), and actin (E). Western blots shown are representative of 3 separate experiments.  In 12 
h transwell chemotaxis assay, cells were pretreated with 50 μM LY 294002 (B) or 20 μM PD 98059 (D)  for 45 
minutes prior to the addition of APC (10 μg/mL).  Cells migrated toward 10% FBS containing media for 12 h.  
Graphs represent the averages of 9 experiments for (B) and 8 experiments for (D). * p<0.05, ** p<0.01, *** 
p<0.001 compared to No Treatment; aa p<0.01 compared to APC treatment.  
 
52 
 
viability was measured using a MTT assay. MDA-MB-231 cell viability increased in the 
presence of EGF or EGF and mIgG compared to No Treatment (Figure 3.5B).  This increase was 
abrogated by a blocking antibody to EGFR (20 µg/mL). In the transwell invasion and chemotaxis 
assay, APC increased invasion approximately 200% over No Treatment and chemotaxis 
approximately 150% (Figure 3.5C). Treatment with EGFR blocking antibody alone had no effect 
on cell migration (Figure 3.5C).  In contrast, the EGFR blocking antibody substantially reduced 
APC-promoted invasion and chemotaxis of the MDA-MB-231 cells (Figure 3.5C). These results 
indicate that in addition to EPCR and PAR-1, a third receptor, EGFR, is involved in the APC-
promoted chemotaxis and invasion of the MDA-MB-231 cancer cell line.  
 APC Promotes MDA-MB-231 Breast Cancer Invasion through MMPs.  Having observed 
that MMPs are involved in APC mediated angiogenesis in our ex vivo aortic ring model, we 
investigated whether MMPs, specifically MMP-2 and/or MMP-9, are involved in the increased 
invasion of MDA-MB-231 cells in response to APC.  It has previously been suggested that APC 
may directly activate MMPs or increase MMP expression [11-13] through NFκB activation [33, 
34], which could occur downstream of PI3K and MAPK pathways.    Our results suggest that 
despite NFκB activation, as evidence by degradation of the NFκB inhibitory protein IκB-α [35] 
(Figure 3.6A, inset), no statistically significant changes in MMP-2 or MMP-9 RNA occurred in 
response to APC.  Furthermore, we did not see any evidence of increased protein levels of pro-
MMP-2/9 or activated MMP-2/9 fragments as measured by immunoblot (data not shown). 
 Despite the lack of altered expression and activity of MMP-2/9 in response to APC, we 
reasoned they might still be involved in elevated invasion of MDA-MB-231 cells based on our 
results with the murine aortic ring assay.  First, a broad-spectrum hydroxamate inhibitor of 
MMPs, GM 6001, was used to determine if MMPs have a role in APC promoted invasion of the  
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 Figure 3.5. APC promoted invasion and chemotaxis of MDA-MB-231 cells is dependent 
upon activation of EGFR. (A) Immunofluorescence on the MDA-MB-231 cell monolayer for EGFR. (B) 
Cells were pretreated with EGFR antibody or control mouse serum IgG (20 µg/mL) prior to the addition of 1 nM 
EGF in SFM. Cells were allowed to grow for 48 h and then treated with MTT. Graphs represent the average 
absorbance for each condition for 4 separate experiments. (C) Cells were pretreated with 20 μg/mL anti-EGFR or 
control mouse serum IgG for 15 minutes prior to the addition of APC (10 μg/mL). Cells invaded for 24 h and 
chemotaxed for 12 h towards 10% FBS containing media. Graphs represent the average of 4 separate experiments 
for invasion and 3 separate experiments for chemotaxis assays; * p<0.05, ** p<0.01 compared to No Treatment; a 
p<0.05 compared to APC treatment; b p<0.05, bb p<0.01 compared to mIgG treatment.  
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MDA-MB-231 cells. As shown in Figure 3.6B, GM 6001 treatment reduced invasion compared 
to No Treatment in a concentration dependent manner as expected due to the reduction of active 
proteases that can degrade the ECM. GM 6001 and APC together yielded similar results. 
Because the GM 6001 MMP inhibitor is a broad-spectrum inhibitor, we also used an inhibitor 
with specificity for only MMP-2 and -9, SB-3CT, to determine if these MMPs were involved in 
APC-promoted cell invasion. Invasion was reduced in a concentration dependent manner upon 
SB-3CT treatment alone as expected (Figure 3.6C). With SB-3CT and APC treatment, we see a 
similar trend (Figure 3.6C). APC activity assays verified that neither GM 6001 nor SB-3CT had 
an effect on APC activity (data not shown). Combined with the data in Figure 3.6A, these results 
imply that MMP activity is necessary for APC induced invasion of MDA-MB-231 cells but that 
APC does not significantly increase MMP-2/9 activity or expression levels in these cells.   
 APC Does Not Increase MDA-MB-231 Breast Cancer Cell Invasion Through the 
Plasminogen Activation System.  It was previously hypothesized that APC promotes invasion in 
ovarian and choriocarcinoma cells by altering the balance between uPA and PAI-1 to favor uPA 
proteolytic activity.  If APC were to enhance uPA proteolytic activity, it is possible that the 
observed changes in PI3K, MAPK, and EGFR activity associated with APC treatment could be 
mostly due to uPA.  We therefore examined this hypothesis with the MDA-MB-231 cell line 
which expresses both uPA and PAI-1.  mRNA levels of uPA and PAI-1 were not altered in the 
presence of APC (data not shown). To determine if APC was altering the level of free uPA in the 
media, transwell invasion assays were performed with amiloride, a small molecule inhibitor of 
uPA, and a blocking antibody to uPA with APC.  As shown in Figure 3.7A, APC or APC and 
DMSO increased invasion of the MDA-MB-231 cells greater than 150%. The amiloride 
treatment alone reduced invasion to approximately 70% of No Treatment. This result was  
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 Figure 3.6: APC promoted invasion of MDA-MB-231 cells is dependent upon MMP-2 and 
MMP-9 degradation of the extracellular matrix. (A) Cells were treated with increasing concentrations 
of APC (0.1, 1, and 10 μg/ml) and assayed for MMP-2 and MMP-9 expression by quantitative PCR and NFκB 
activation by immunoblot of IκB-α (inset).  For invasion assays, cells were pretreated with increasing 
concentrations of GM 6001 (0-25 μM; B) or SB-3CT (0-10 μM; C) for 15 minutes prior to the addition of 10 μM 
APC. Cells invaded towards 10% FBS containing media for 24 h. Graphs represent the averages of 8 separate 
experiments; * p<0.05, ** p<0.01 compared to No Treatment; a p<0.05, aa p<0.01, aaa p<0.001 compared to APC 
treatment. 
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expected since uPA was inhibited, reducing the activation of plasminogen and MMPs, which 
mediate cellular invasion. If uPA was a key component to the mechanism by which APC 
promoted invasion, then the treatment of APC and amiloride should have the same result as 
amiloride treatment alone. However, APC still increased invasion of the MDA-MB-231 cells 
even when uPA was inhibited, indicating that APC promotes cell invasion through a mechanism 
other than through uPA. APC activity assays verified that APC was not inhibited by amiloride 
(data not shown). To further confirm that uPA was not involved in the mechanism, a blocking 
antibody to the active site of uPA was used in the transwell invasion assay (Figure 3.7B). As was 
found with amiloride, even in the presence of the uPA blocking antibody, APC was able to 
increase cell invasion approximately 150% compared to No Treatment.  
 To determine if PAI-1 has a role in APC-promoted increase in invasion, a blocking 
antibody to PAI-1 was used along with APC in the transwell invasion assays (Figure 3.7C). In 
contrast to control goat IgG, the blocking antibody to PAI-1 increased invasion approximately 
the same amount compared to APC. With limited PAI-1 activity to inhibit uPA, the serine 
protease can more freely activate proteases that degrade the ECM, such as plasminogen and 
MMPs. Interestingly, the addition of APC with the blocking antibody to PAI-1 had an additive 
effect, increasing invasion further (to approximately 350% compared to No Treatment) over 
PAI-1 blocking antibody alone (Figure 3.1C). These results suggest that APC promotes invasion 
of the MDA-MB-231 cells by a mechanism distinct from altering the ratio between uPA and 
PAI-1 that favors uPA proteolytic activity.  
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Figure 3.7: APC does not increase invasion of the MDA-MB-231 cells through the 
plasminogen activator system. Cells were pretreated with 0.2 mM amiloride (A), 20 μg/mL anti-uPA (B), 
20 μg/mL anti-PAI-1 (C), and corresponding control antibodies for 1 h prior to the addition of 10 μg/mL APC. Cells 
invaded and migrated towards 10% FBS containing media for 24 h. Graphs represent the average of 3 separate 
experiments; * p<0.05, ** p<0.01 compared to No Treatment; a p<0.05, aaa p<0.001 compared to APC treatment; b 
p<0.05, bb p<0.01 compared to amiloride/anti-uPA/anti-PAI-1 treatment. 
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Discussion 
In this study, we utilize in vitro and ex vivo models to show that APC can promote 
angiogenesis in both human and murine endothelial cells through MMP activation and EGFR 
transactivation – mechanisms that have been proposed for APC mediated motility in other cell 
types.   Furthermore, based on previous findings and our own observations, we extended this 
examination to determine the mechanisms that govern APC promoted motility and invasion in 
MDA-MB-231 breast cancer cells.  In both cell types, we found a common pathway whereby 
APC promotes angiogenesis and invasion, by activating MMPs and activating EGFR.  Using 
blocking antibodies to EPCR, PAR-1, and EGFR with the breast cancer cells, we found that APC 
interacts with all three receptors to promote invasion.  Our results imply that interaction of these 
three receptors with APC activates the PI3K and MAPK pathways and that activation of these 
pathways is necessary for APC to promote migration and invasion.   
APC increases HUVEC invasion and migration at optimal concentrations of 0.1 µg/mL 
and 0.5 µg/mL, respectively.  Furthermore, APC promotes tube like structures in HUVEC at 0.1 
μg/ml.  These two concentrations of active protease (0.1 μg/ml = 1.8 nM and 0.5 μg/ml = 8.8 
nM) are significantly lower than zymogen PC in plasma (~4 µg/mL or ~71 nM), from which the 
active protease is derived, and are much less then what have been previously used to show that 
APC promotes HUVEC proliferation and tube formation [20].  However, these concentrations of 
APC are similar to those used previously to show that APC can regulate intracellular calcium 
fluxes [36].  Therefore, the effects of APC described here with HUVEC are likely relevant to 
physiological concentrations of protein C/APC.  By contrast, while higher concentrations of APC 
were required to detect statistically significant changes in chemotaxis and invasion transwell 
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assays with the MDA-MB-231 cells, 0.1 μg/ml APC was sufficient to activate PI3K and MAPK 
signaling.  
 Besides activation of PI3K and MAPK signaling, we also observed activation of NFκB 
in the MDA-MB-231 cells in response to APC, a finding which contrasts observations in other 
cell types.  Notably, APC has been shown to inhibit endotoxin induced NFκB nuclear 
translocation in monocytic cells [37] and APC down--regulates tPA induced NFκB activity in 
ischemic endothelial cells, thereby reducing MMP-9 activation [38].  The precise mechanism by 
which APC could instead activate NFκB in breast cancer cells remains unclear.  However, cross-
talk between PI3K, MAPK, and NFκB is possible, given the observation that breast cancer cells 
exhibit a unique positive correlation between PI3K/MAPK signaling and NFκB activation [39-
41]. 
Using the murine ex vivo aortic ring assay, we show that APC increases sprout formation 
of vWF-positive endothelial cells and that this effect is dependent on MMP and EGFR 
activation.  Notably, this phenomenon was only observed at a higher concentration of APC (10 
μg/ml) than the optimal concentration observed for human cells in culture.  In one study, the 
concentration of human APC that effectively reduced the volume of cerebral infarct and 
increased cerebral blood flow post-onset of stroke in mice was 2 mg/kg [42].  In contrast, similar 
studies done with murine APC showed that the same beneficial effects can be seen using 10 
times less, 0.2 mg/kg [38, 43].  Therefore, it is likely that the requirement for higher 
concentrations in the murine aortic ring assay is a function of species differences, further 
suggesting that the effects of APC observed in this study are relevant to physiological 
concentrations of APC/PC.   
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 Using pharmacological inhibitors in the transwell chemotaxis assays, along with western 
blot analysis, we show that APC activates the PI3K and MAPK pathways to increase motility of 
the MDA-MB-231 cells.  Based on this study and our results of chemotaxis [23], we suggest that 
APC is focused at the cell surface through its binding to EPCR and that PAR-1 is subsequently 
cleaved by APC-bound to EPCR [38].  Furthermore, the results suggest that APC also 
transactivates EGFR, and that this activity is required to promote motility in the MDA-MB-231 
cells.   
 There are many possible mechanisms whereby PAR-1 and EGFR could work in concert 
in response to APC to promote motility via activation of PI3K and MAPK signaling.  First, APC 
could bind directly to EGFR, like recently shown for another serine protease, tissue plasminogen 
activator [44], and directly activate MAPK signaling through Ras [45]. Second, PAR-1 
activation mediated by APC cleavage would lead to Gα or β/γ subunits activating c-Src.  c-Src 
can directly activate PI3K and could also mediate phosphorylation of Tyr 845 on the cytoplasmic 
tail of EGFR [46], subsequently activating MAPK signaling via Ras.  There is proof of principle 
for this mechanism.  Via EPCR and PAR-1, APC has been shown to transactivate another 
receptor, sphingosine-1-phosphate1 receptor, which affects vascular permeability of endothelial 
cells [47].  Third, PAR-1 could possibly activate the TNF-alpha converting enzyme (TACE; 
ADAM-17), a membrane-bound disintegrin metalloprotease that processes membrane-associated 
cytokines such as heparin bound-EGF (HB-EGF) or other EGFR-family member ligands to 
transactivate EGFR [48, 49].  HB-EGF would bind to the ligand-binding domain of EGFR, 
leading to the phosphorylation of the receptor and activation of Ras [50-52].  In any mechanism 
in which Ras is activated, there is a potential for PI3K activation as Ras has been shown to 
directly activate PI3K [53].  Our results do not favor the direct activation of EGFR by APC, but 
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suggest that APC-EPCR interactions through PAR-1 promote either the transphosphorylation of 
EGFR (since the EGFR blocking antibody reduced motility in the presence of APC) or by 
ADAM-17-directed ligand transactivation (since the MMP inhibitor GM 6001 is also known to 
inhibit ADAM-17). 
 Within the context of the MDA-MB-231 breast cancer cells, our results suggest a shift 
away from other mechanistic paradigms that suggest the primary role of APC in motility 
involves the regulation of pericellular proteolysis.  There is prior evidence that APC directly 
activates MMPs, specifically MMP-2.  Through zymography, APC was also shown to activate 
MMP-2 from the intermediate to fully active form [16, 18, 54], independent of MT1-MMP [16, 
54]. Additionally, it has also been shown that solution phase APC [16, 54] and APC generated 
on the cell surface in the presence of thrombin bound to TM can activate MMP-2 [18].  
Furthermore, it has been suggested that APC can promote increased expression of MMP-2 [17, 
19].  In our study we found that MMP activity, specifically MMP-2 and MMP-9 activity, is 
required for APC to promote invasion.  However, we did not observe significant changes in 
either MMP-2 or MMP-9 RNA expression.  We also did not observe differences in protein levels 
of pro-MMP-2/9 or any difference in the amount of active MMP2/9 in culture media in response 
to APC.  These results suggest that while some basal level of MMP-2/9 activity is required to 
initiate pericellular proteolysis of the extracellular matrix in response to APC, treatment with 
APC is not significantly increasing MMP expression or activity in the MDA-MB-231 cells.  It is 
likely that high levels of uPA as well as signaling cascades that can promote MMP expression, 
such as MAPK signaling, lead to high basal activity and expression of MMP-2/9 that is not 
significantly altered by APC treatment.   
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 In a similar regard, our results with the MDA-MB-231 cells also differ from previous 
studies which suggest that APC promotes motility through inhibition of PAI-1 with subsequent 
activation of uPA.  Kobayashi, et al. [10] found that exogenously added APC increased invasion 
of cancer cells in vitro by forming a stable complex with the serpin, PAI-1 and thereby APC 
promotes invasion by increasing uPA activity [10].  However, in our study, blocking uPA with 
either the chemical inhibitor amiloride or a blocking antibody to its active site did not alter the 
ability of APC to promote invasion of the MDA-MB-231 breast cancer cells.  Moreover, in the 
presence of a PAI-1 blocking antibody and APC, there was an additive effect to promote 
invasion.  The observation that APC does not promote motility through the plasminogen 
activator system, taken together with our findings about the role of MMP’s in breast cancer cell 
motility, suggests that APC promotes motility of the MDA-MB-231 cells largely as a 
consequence of its ability to activate EGFR, MAPK, and PI3K associated signaling cascades.   
 In summary, our results show that APC promotes endothelial motility via activation of 
EGFR and MMP’s, both in vitro and ex vivo.  With regard to our unique findings with the MDA-
MB-231 cells, our results show an interesting interdependent nature of the pathways that are 
activated by APC to increase motility. Blocking of any one of the three involved receptors, 
(EPCR, PAR-1 or EGFR), or inhibition of MMP-2 and/or MMP-9 results in a loss of the increase 
in motility promoted by APC.  Overall, the effect of APC is coordinated with both intracellular 
activation of signaling pathways, which promote motility, and with some level of pericellular 
activation of MMPs, which primes the cells to respond to chemoattractants at an increased rate. 
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Abstract 
 In hemostasis, the serine protease inhibitor (serpin) plasminogen activator inhibitor-1 
(PAI-1) functions to stabilize clots via inhibition of tissue plasminogen activator (tPA) with 
subsequent inhibition of fibrinolysis.  In tissues, PAI-1 functions to inhibit extracellular 
matrix degradation via inhibition of urokinase plasminogen activator (uPA).  Elevated levels 
of PAI-1 in the vasculature and in tissues have long been known to be associated with 
thrombosis and fibrosis, respectively.  However, there is emerging evidence that PAI-1 may 
participate in the pathophysiology of a number of diseases such as atherosclerosis, restenosis, 
and cancer.  In many of these disease states, the canonical view of PAI-1 as an inhibitor of 
tPA and uPA cannot fully account for a mechanism whereby PAI-1 contributes to the 
disease.  In these cases, one must consider recent data, which indicates PAI-1 can directly 
promote pro-proliferative and anti-apoptotic signaling in a variety of cell types.  Given the 
wide variety of inflammatory, hormonal, and metabolic signals that increase PAI-1 
expression, it is important to consider mechanisms by which PAI-1 can directly participate in 
disease etiology.   
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Introduction 
Traditional paradigms for PAI-1 in fibrinolysis and tissue remodeling 
 Within the intravascular space, the primary role for the serpin (serine protease 
inhibitor) PAI-1 is to regulate fibrinolysis to stabilize hemostatic plug formation.  When 
bound to fibrin in a clot, the serine protease tissue plasminogen activator (tPA) activates 
plasminogen to its active form of plasmin, which subsequently degrades fibrin [1].  During 
thrombus formation, tPA is inhibited by PAI-1 released from platelets [2], thereby limiting 
further plasminogen activation and fibrinolysis.   
The primary role of PAI-1 in the extravascular space is to regulate matrix remodeling 
via inhibition of the urokinase plasminogen activator (uPA) [3].  uPA bound to cells 
expressing its cognate receptor uPAR, can catalyze the pericellular conversion of 
plasminogen to plasmin, which can subsequently cleave and/or activate numerous proteins 
such as gelatinase, fibronectin, laminin, and latent forms of collagenases including MMP-1 to 
lead to matrix degradation.  As with tPA, PAI-1 forms a 1:1 complex with uPA and renders 
the protease inactive, thereby inhibiting pericellular proteolysis. 
 PAI-1 has also been implicated in inhibiting adhesion of cells to extracellular matrix 
proteins, although the precise mechanism remains debated.  uPAR has been shown to 
associate with multiple different integrin subunits and it has been suggested that uPAR can 
act as an integrin ligand to promote both cell adhesion to various matrix proteins [4], as well 
as cell to cell adhesion [5].  Given these findings, it has been suggested that PAI-1 may 
promote de-adhesion from various substrata via destruction of integrins [6].  Alternatively, is 
has been suggested that PAI-1 can promote de-adhesion specifically for the extracellular 
matrix protein vitronectin (VN) [7].  PAI-1 and uPAR/uPA complexes compete for binding 
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to VN [7], and binding of PAI-1 to uPA dissociates uPAR from vitronectin.  Endocytosis of 
the uPAR/uPA/PAI-1 ternary complex by the low-density lipoprotein-like receptor 1 (LRP-1) 
then promotes de-adhesion of cells from VN [8].   
 
Regulation of PAI-1 expression in the intravascular and extravascular space 
 During the initiation of thrombus formation, release of PAI-1 by platelets represents 
the most likely primary source of PAI-1 [2].  However, multiple cell types are capable of 
producing PAI-1 in response to various inflammatory cytokines.  The multiplicity of 
potential sources of PAI-1 as a response factor has implications for PAI-1 function in both 
physiological and pathophysiological conditions.   
 As a recognized acute phase reactant, PAI-1 levels in plasma increase quickly in 
response to vessel injury and a heightened inflammatory state [9].  Like C-reactive protein 
(CRP) and fibrinogen, PAI-1 levels in plasma have been shown to increase in response both 
to acute trauma such as local tissue injury [10] and to chronic inflammatory states such as 
cardiovascular disease [11] and insulin resistance [12].  In mouse models, this increase has 
been attributed to increased synthesis of PAI-1 by the liver in response to inflammatory 
cytokines IL-1β [10], IL-6 [13], and tumor necrosis factor-α (TNFα) [14].  Under 
physiological conditions, acute increases in the plasma concentration of PAI-1 in response to 
inflammatory cytokines could be viewed as a mechanism to stabilize thrombus formation by 
inhibiting tPA-mediated plasminogen activation.  However, under pathological conditions 
such as atherosclerosis, sustained elevated levels of PAI-1 could promote thrombosis.     
 In contrast to fast up-regulation of PAI-1 in plasma as an acute phase reactant, there 
are also mechanisms by which PAI-1 levels in the intravascular space may be up-regulated in 
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a more sustained fashion via endothelial cell production.  Similar to hepatocytes, cultured 
endothelial cells have been shown to increase PAI-1 production in response to the 
inflammatory cytokines IL-1 [15] and TNF-α [16].  PAI-1 synthesis by endothelial cells has 
also been shown to increase as a consequence of hypoxia [17], the generation of reactive 
oxygen species [18], and shear stress [19].  Alternatively, increased PAI-1 production by 
endothelial cells has also been associated with senescence, a process that increases with age 
[20].  
 Extravascularly, regulation of PAI-1 expression involves multiple cell types.  In 
fibroblasts, PAI-1 synthesis is increased in response to TGF-β [21] and IL-6 [22].  Perhaps 
the most important source of PAI-1 in tissues is adipocytes.  Mature adipocytes express 
relatively high basal levels of PAI-I in culture [23].   Despite high basal expression, 
adipocytes can increase PAI-1 synthesis in response to many cytokines and hormones such as 
TNF-α, TGF-β, and insulin [24].  Finally, macrophages represent another source of PAI-1 in 
the extravascular space.  Activation of monocytes with endotoxin increases PAI-1 expression 
and histological studies indicate that tissue macrophages in artheromatous plaques express 
PAI-1 [25]. 
 Given the diversity of cellular sources and multitude of inflammatory signals which 
promote PAI-1 expression, it is not surprising that elevated PAI-1 levels in serum and tissue 
have been observed in a variety of pathological conditions.  One might suggest elevated PAI-
1 levels could be merely a marker of inflammation.  However, multiple studies have shown 
that PAI-1 participates directly in the pathophysiology of a number of diseases.  In some 
cases, the traditional paradigms for the function of PAI-1 can fully explain its role in 
pathology. Alternatively, in other disease states, the traditional paradigms for the function of 
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PAI-1 are not sufficient to understand its participatory role.  Thus, new data are emerging 
that strongly suggests PAI-1 has novel functions far beyond its ability to inhibit tPA and 
uPA.   
 
Pathologic consequences of PAI-1 expression explained by traditional paradigms 
 PAI-1 in thrombosis- As an inhibitor of plasminogen activation and fibrin 
degradation, it is logical that elevated PAI-1 levels in serum would lead to thrombosis.  With 
regard for thrombosis in the coronary arteries, elevated PAI-1 levels have been documented 
in the serum of survivors of a myocardial infarction and patients that have recurrent 
myocardial infarctions [26].  In an experimental model, transgenic mice that express a stable 
form of human PAI-1 develop spontaneous coronary thrombi [27].  Elevated levels of PAI-1, 
especially in the elderly, are thought to be associated with both venous and arterial 
thrombosis [28]. 
PAI-1 in fibrosis- In tissues, increased expression of PAI-1 has been associated with 
multiple forms of fibrosis including glomerulosclerosis [29], liver fibrosis [30], and 
pulmonary fibrosis [31].  While there are competing schools of thought on the role of PAI-1 
in promoting fibrosis, all utilize the traditional paradigm for PAI-1 function.  First, it is 
thought that elevated PAI-1 expression decreases tPA/uPA activity leading to increased 
fibrin deposition at the site of a vessel injury.  Due to the increased fibrin deposition, more 
cells infiltrate the wound, leading to increased collagen deposition.  In an alternative model, 
it has been suggested elevated PAI-1 promotes de-adhesion, allowing for more cells to 
infiltrate.  Finally, it has also been suggested that the primary consequence of elevated PAI-1 
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is actually decreased collagenase activity downstream of reduced uPA and MMP activation.  
In this model PAI-1 directly promotes fibrosis by inhibiting collagen degradation [32].    
In contrast to observations linking PAI-1 to thrombosis and fibrotic disease, the role 
of PAI-1 in other pathological conditions are not explained by traditional paradigms, which 
focus solely on the protease inhibitor activity of PAI-1.  More recent studies elucidating the 
ability of PAI-1 to alter cell signaling is providing insight to explain how PAI-1 can 
contribute to other disease states.   
 
Pathologic consequences of PAI-1 expression not explained by traditional paradigms 
PAI-1 in vascular disease- PAI-1 has a well-documented association with the 
development of vascular disease.  Multiple studies have demonstrated the presence of excess 
PAI-1 in atherosclerotic plaques [25, 33, and 34].  Furthermore, PAI-1 deposition in the 
vascular wall [35], and atherosclerotic plaques [36], is elevated in patients with type II 
diabetes.  This is not surprising given that elevated PAI-1 expression has been directly linked 
to hyperinsulinemia as well as glucose/lipid imbalance [37].   
It has been suggested that the presence of PAI-1 in atherosclerotic plaques may 
directly contribute to atherogenesis primarily via inhibition of MMP activation with 
subsequent decreased activation of TGFβ [38], which promotes smooth muscle cell 
proliferation, and decreased processing of cholesterol aggregates [26].  However, there are 
other mechanisms by which PAI-1 may promote the development of atherosclerosis that 
reach beyond the traditional paradigms of tPA/uPA inhibition.  Of note, PAI-1 has shown to 
directly promote migration, inhibit apoptosis [39], and promote proliferation [40] of smooth 
muscle cells.  These studies elucidate that PAI-1 has unique capabilities to promote cell 
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signaling.  With regard to apoptosis and proliferation, these studies show purified PAI-1 
inhibits caspase-3 activity in vitro [39], and promotes cell proliferation via activation of the 
NFκB and ERK signaling [40].  Given the importance of smooth muscle cell proliferation in 
the development of atherosclerotic lesions, it is important to consider the potential role of 
PAI-1 directly mediating intracellular signaling events in vascular disease.    
Another interesting potential mechanism of PAI-1 mediated signaling in vascular 
disease involves macrophages recruitment.   In in vitro studies, PAI-1 in combination with 
tPA and LRP-1 (the co-receptor for clearance of tPA-PAI-1 and uPA-PAI-1 complexes), has 
been shown coordinate Mac-1 dependent macrophage migration [41].  While the authors of 
these studies suggest PAI-1 mediated migration of macrophages is a function of the de-
adhesive functions of PAI-1, it is likely to involve more complicated signaling events in light 
of data which shows the LRP-1 co-receptor acts as a motogenic receptor for PAI-1, and can 
activate Jak/Stat signaling when it binds PAI-1 [42].   
 
PAI-1 in the tumor microenvironment  
The tumor microenvironment represents a heterogeneous mixture of cell types, many 
of which can produce and respond to PAI-1, including the tumor cells themselves.  
Considering the well documented role of the immune system and inflammation in cancer and 
the tight linkage between inflammation and elevated PAI-1, one might hypothesize that PAI-
1 could play a direct role in the pathophysiology of cancer.  This hypothesis should garner 
close investigation given that elevated PAI-1 levels in the tumor microenvironment correlates 
to poor prognosis in multiple cancers including breast [43], ovarian [44], pulmonary 
adenocarcinoma [45], and neuroblastoma [46].  The commonly observed elevation of PAI-1 
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in cancer presents a difficult paradox. Given the well-documented association of matrix 
degradation with tumor viability and metastasis, one would expect that PAI-1, as an inhibitor 
of uPA, would represent a positive prognostic indicator.  However, insights into the novel 
functions of PAI-1 as a cell signaling mediator may help explain why PAI-1 is often a poor 
prognostic indicator.   
Most directly, PAI-1 produced by adipocytes, fibroblasts, or macrophages in response 
to various cytokines in the tumor microenvironment can promote angiogenesis, which is 
crucial to tumor viability and dissemination.  While not without controversy, PAI-1 is 
generally accepted to promote angiogenesis in the tumor microenvironment.  Utilizing PAI-1-
/- mice, it has been shown PAI-1 promotes angiogenesis in the tumor microenvironment at 
low concentrations but inhibits angiogenesis at extremely high concentrations [47].  The 
precise mechanism by which PAI-1 promotes angiogenesis has remained largely elusive, 
although it has been suggested that the ability of PAI-1 to promote angiogenesis is dependent 
on it protease inhibitor activity, not vitronectin binding [48].  This finding would suggest 
PAI-1 does not promote angiogenesis by promoting de-adhesion of endothelial cells from 
matrix proteins.  The most complete study analyzing angiogenesis suggests that PAI-1 
inhibits pro-apoptotic cell signaling by inhibiting plasmin mediated cleavage of Fas-ligand 
on the surface of endothelial cells [49].  This represents a novel mechanism for how PAI-1 
prevents apoptosis of endothelial cells and therefore promotes angiogenesis.   
Another mechanism whereby PAI-1 could function to promote cancer dissemination 
comes from a novel finding with senescence in fibroblasts.  PAI-1 has long been known as a 
marker of senescence in multiple cell types [50, 51].  However, it has been shown that PAI-1 
is not only a marker of senescence in fibroblasts, but that it is a critical downstream target of 
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p53 in the induction of senescence, through a PI3K-dependent pathway [52].  If PAI-1 can 
participate directly in the induction of replicative senescence, it is possible that an excess of 
PAI-1 in the tumor microenvironment could induce the senescence of fibroblasts, leading to 
decreased deposition of matrix.    
Outside of its influence on endothelial cells and fibroblasts in the tumor 
microenvironment, emerging data suggests PAI-1 has direct influence over pro-proliferative 
and anti-apoptotic signaling in tumor cells themselves.  While mouse models designed to 
examine the effect of PAI-1 on tumor development have yielded often-conflicting data [53], 
in vitro examination of various cancer cell lines indicates that PAI-1 has a positive influence 
on cancer cell growth and survival.  While limited, this data may provide the most direct link 
to explain why elevated PAI-1 levels are associated with poor prognosis in cancer.   
One such study demonstrated that both the PC-3 prostate cancer cell line and the HL-
60 promyelocytic cell line demonstrated decreased apoptosis in the presence of PAI-1 when 
treated with apoptosis inducing agents camptothecin or etoposide [54].   Similarly, our 
laboratory has found that stable expression of wild type PAI-1, but not an inactive mutant of 
PAI-1, enhances the recovery of MDA-MB-435 cancer cells after exposure to apoptosis 
inducing agent paclitaxel [55], and enhances motility and adhesion via alteration of the 
integrin profile at the cell surface [56].  Fibrosarcoma cell lines derived from PAI-1-/- mice 
were significantly more sensitive to apoptotic stimulus etoposide than counterpart 
fibrosarcoma cell lines from wild type mice [57]. 
More recent data reveals how PAI-1 may influence cancer cell viability via direct 
alteration of cell signaling.  An expanded analysis of the murine fibrosarcoma cells discussed 
above revealed that PAI-1 deficient fibrosarcomas have reduced Akt signaling and re-
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introduction of PAI-1 expression in deficient cells results in an increase in Akt signaling 
[58].  Our laboratory has found that stable knockdown of PAI-1 expression in MDA-MB-231 
breast cancer cells results in decreased Akt activation (Gramling, M.W. and F.C. Church, 
unpublished data).  Besides regulation of anti-apoptotic Akt signaling, PAI-1 has also been 
shown to activate pro-proliferative MAPK signaling.  In MCF-7 breast cancer cells, PAI-1 
promotes sustained phosphorylation of ERK1/2 via a mechanism which is dependent on its 
interaction with uPA as well as the activity of uPAR and the LRP-1 co-receptor (59).  This 
study further showed that the presence of PAI-1 allowed uPA to act as a mitogen for the 
breast cancer cells [59].   
 
Conclusion 
Given that PAI-1 expression is elevated both the intra- and extra-vascular space by 
such a wide variety of inflammatory, hormonal, and metabolic signals, it has potential to 
influence many physiological and pathophysiological conditions.   The pleiotropic effects of 
PAI-1 are diagrammed in Figure 4.1.  From thrombosis and fibrosis to atherosclerosis and 
cancer, PAI-1 directly contributes to the etiology of disease via mechanisms explained by 
traditional paradigms of its function and by new mechanisms explained by its emerging role 
in altering cell signaling.   
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Figure 4.1. PAI-1 has been implicated in modulating a variety of physiological and pathophysiological 
processes.  PAI-1 expression in the intra- and extra-vascular space is increased in response to many 
inflammatory, hormonal, and metabolic signals.  By modulating protease activity, adhesion, and altering 
signaling in multiple cell types, PAI-1 can contribute to many normal and disease processes.   
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Abstract 
 Both urokinase plasminogen activator (uPA) and its inhibitor, plasminogen activator 
inhibitor-1 (PAI-1), are clinically recognized markers of poor prognosis in breast cancer.  In 
this study we examined if uPA and PAI-1 can directly contribute to the cellular 
pathophysiology of breast cancer cells utilizing MDA-MB-231 and MDA-MB-436 cells as a 
model system.  uPA and PAI-1 activity were inhibited, and shRNA constructs targeted 
against uPA and PAI-1 RNA were used to establish stable knockdown in MDA-MB-231 
cells.  Catalytic inhibition of both uPA and PAI-1 activity inhibited MAPK and PI3K 
activities and reduced growth in a three dimensional extracellular matrix (ECM).  uPA and 
PAI-1 inhibitor treatments of both MDA-MB-231 and MDA-MB-436 breast cancer cells 
inhibited cell growth in low serum conditions.  As expected, MDA-MB-231 cells with stable 
knockdown of uPA exhibited reduced MAPK activity and reduced growth in low serum 
conditions relative to cells carrying a non-targeted lentivirus (pLKO), but were not sensitized 
to chemotherapeutic agents.  MDA-MB-231 cells with PAI-1 knockdown exhibited reduced 
PI3K activity and MAPK activity and displayed a similar growth defect in low serum and in 
a three dimensional ECM.  To more closely assess the cause of the unique growth defects 
observed for PAI-1 knockdown cells, their basal proliferative capacity versus sensitivity to 
apoptosis was examined. PAI-1 knockdown did not lead to reduced staining for proliferation 
marker Ki67 but did result in increased staining for the apoptosis marker active Caspase-3.  
PAI-1 knockdown led to sensitization of cells to chemotherapeutic agents paclitaxel, 
doxorubicin, and cisplatin. Furthermore, PAI-1 inhibitor treatment of MDA-MB-436 cells 
caused similar sensitization to all three chemotherapeutic agents.   Collectively, these results 
suggest that PAI-1 may protect cancer cells from apoptosis thereby directly participating in 
the cellular pathophysiology of breast cancer.   
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Introduction 
The plasminogen activator (PA) system is well documented as a key player in the processes 
of matrix remodeling and cell motility [1]. At the cell surface, the serine protease urokinase 
plasminogen activator (uPA) is bound to its cognate receptor uPAR.  This interaction 
promotes the ability of uPA to activate pericellular plasminogen to its active form, plasmin 
[2] which can degrade multiple matrix proteins including fibronectin and laminin as well as 
activate multiple matrix metalloproteinases (MMPs) [3].  In addition, uPA and uPAR are 
thought to directly promote cell motility with the interaction of uPAR with integrins [4], uPA 
mediated activation of multiple components of focal adhesion components [5], and specific 
binding of uPAR to the extracellular matrix (ECM) protein vitronectin [6].  The primary 
physiological inhibitor of uPA is PAI-1 [7,8].  When the reactive center loop of PAI-1 binds 
to the active site of uPA, a covalent 1:1 stoichiometric complex is formed. The trimeric 
complex of uPAR/uPA/PAI-1 is subsequently bound by the low density lipoprotein like 
receptor 1 (LRP-1), which catalyzes endocytosis of the entire complex [9,10]. Notably, PAI-
1 also binds vitronectin [11,12] and competes against uPAR mediated adhesion to vitronectin 
[13].   
 Given the contributions of uPA/uPAR to proteolysis and cell motility it is logical that 
elevated uPA/uPAR expression would be associated with increased metastasis and therefore 
poor prognosis.  In fact, this has been demonstrated in esophageal, gastric, colorectal, small 
cell lung, osteosarcoma, ovarian, prostate, and breast cancer among others [14]. This 
association is complemented by studies demonstrating that uPA/uPAR can stimulate both 
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proliferative and anti-apoptotic signaling [15,16].  However, a paradox emerges regarding the 
PA system’s association with cancer because PAI-1 elevation is also associated with poor 
prognosis in a number of cancers including ovarian [17], pulmonary adenocarcinoma [18], 
neuroblastoma [19], and breast [20].  Effectively, if the physiological role of PAI-1 is to 
inhibit uPA protease activity, it is unclear how elevated PAI-1 could be associated with poor 
prognosis in the context of metastatic potential and proliferative/anti-apoptotic signaling.  
This “PAI-1 Paradox” is especially important in breast cancer, as elevation of both uPA and 
PAI-1 has been demonstrated to be a strong predictor of poor prognosis in breast cancer at 
the highest levels of significance using a level of evidence 1 (LOE-1) study [21]. 
 In seeking to understand the PAI-1 paradox in tumor biology, previous studies have 
focused on its role in angiogenesis and cell motility. PAI-1 appears to promote angiogenesis 
in a dose dependent manner and prevent apoptosis in endothelial cells [22-25]. Others have 
sought to explain the PAI-1 paradox by showing that PAI-1 may directly promote motility of 
cancer cells by balancing the progressive steps of adhesion and de-adhesion required for cell 
motility [26].  
 Given the strong correlation between expression of uPA and PAI-1 and prognosis in 
breast cancer, in this study we aim to elucidate the direct effects of uPA and PAI-1 on cancer 
cell proliferation and apoptosis using primarily MDA-MB-231 breast cancer cells.  These 
cells are an optimal cell system to examine the role of the PA system in breast cancer cell 
biology because they are unique among common breast cancer cell lines in their expression 
of high levels of both uPA and PAI-1 [27]. In some experiments we utilized the MDA-MB-
436 breast cancer cell line.  While this cell line is less well characterized than MDA-MB-231 
cells, they are reported to make comparable levels of uPA and PAI-1 [27].  The expression of 
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both uPA and PAI-1 by the cells allows us to examine the effect of parallel enzymatic uPA 
and PAI-1 inhibition as well as parallel stable knockdown of uPA and PAI-1, and to assess 
the downstream consequences on both proliferation and apoptosis in multiple experimental 
contexts.   
 
Materials and Methods 
Cell Culture - MDA-MB-231 and MDA-MB-436 cells were obtained from ATCC. MDA-
MB-231 cells were maintained in Minimum Essential Media (MEM; Gibco) with 10% FBS 
(Sigma), 1% sodium pyruvate (Gibco), and 1% antibiotic/antimycotic (Gibco). MDA-MB-
436 cells were maintained in MEM with high glucose (Gibco) supplemented with 10% FBS 
(Sigma), 10 μg/ml insulin (Gibco), 2 mM glutathione (MB Biomedicals), 1% sodium 
pyruvate (Gibco), and 1% antibiotic/antimycotic.  All cells were cultured in an incubator at 
37 °C, 5% CO2.  For MDA-MB-231 cells carrying lentiviral shRNA, media was 
supplemented with 7.5 g/ml puromycin (Sigma).   
Cell Invasion Assays - Invasion assays with MDA-MB-231 cells were performed using BD 
BioCoat™ Matrigel™ Invasion Chambers (BD Bioscience), with an 8-μm diameter pore size 
membrane. Matrigel™ coated membranes, were hydrated in serum-free medium containing 
0.1% bovine serum albumin (BSA) for 2 h at 37°C before the experiment. As a 
chemoattractant, complete media with 10% FBS was added to the lower well of the plate. 
Cells were pre-treated in serum free media for 1 hr with 20 μg/ml goat inhibitory PAI-1 
antibody (395G, American Diagnostica), mouse inhibitory uPA antibody (394, American 
Diagnostica), serum mouse or goat IgG (15256, Sigma), as well as the small molecule uPA 
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inhibitor amiloride (A7410, Sigma) at 0.2mM, seeded at 5 × 10
4
 cells in the culture insert 
with treatments, and incubated for 24 hr at 37°C, 5% CO2.  The number of cells that migrated 
through the membrane was counted via Hoechst staining as described previously [28].  
Growth Assays and Chemotherapeutic Sensitivity Assays - For 7 day growth assays, 1 × 10
4 
 
cells were plated in triplicate in 96 well plates in complete media.  After 24 hr, cells were 
washed with PBS and treated with 1% serum medium containing control DMSO or amiloride 
and control goat IgG (Sigma) or goat PAI-1 inhibitory antibody (395G American 
Diagnostica).  Viability was assessed 24 hr post plating and at days 1, 3, 5, and 7 post 
treatment by 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as 
previously described [29].  Medium with or without inhibitors was replaced every 48 hr.  For 
treatments with chemotherapeutic agents, 2.5 x 10
4
 cells were plated in triplicate in 96 well 
plates.  Cells were serum starved for 24 hr, treated with complete medium containing 100 μM 
paclitaxel, 10 μM doxorubicin, or 10 μM cisplatin for 48 hr, and then assayed by MTT.  For 
MDA-MB-436 cells, cells were treated with 1 μM paclitaxel, doxorubicin, or cisplatin in the 
presence of either 20 μg/ml goat IgG or goat PAI-1 inhibitory antibody.    
Three Dimensional Culture  - Cells were grown in growth factor-reduced basement 
membrane extract (Cultrex)  with protocols adapted from the “3D on top” method of Bissel 
and colleagues [30].  Briefly, 24 well plates were coated with 120 l of basement membrane 
extract.  Sub-confluent cells were trypsinized and re-suspended in complete medium 
supplemented with 10% basement membrane extract with or without uPA and PAI-1 
inhibitory treatments and 3 x 10
4
 cells were seeded onto the wells.  Cells were maintained for 
6 days with re-supplementation of medium containing 10% basement membrane extract plus 
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or minus treatment every 48 hours.  Photomicrographs were obtained on day 6 with and 
Olympus CK40 inverted microscope. 
Immunoblot Analysis – After 24 hours of serum deprivation, whole cell lysates, or 
conditioned medium concentrated by centrifugal filtering devices (Millipore) with a 
molecular weight cutoff of 30 kDa, were separated on 7.5% SDS-PAGE gels and transferred 
onto PVDF membranes (Millipore).  Whole cell lysates were probed for P-ERK1/2 (E-4, 
Santa Cruz Biotechnology), total ERK2 (C-14, Santa Cruz Biotechnology), P-Akt (9271, 
Cell Signaling), or total Akt (9272, Cell Signaling).  Concentrated conditioned medium was 
probed for uPA (American Diagnostica) or PAI-1 (Molecular Innovations).  Densitometry of 
immunoblots was performed using ImageJ software from NIH and results are expressed as 
fraction of phosphorylated signal relative to total ERK2 or Akt.  In experiments assessing the 
effects of purified uPA, PAI-1, or uPA-PAI-1 complex, 50% confluent cells were subjected 
to a mild acid wash to remove cell surface uPA, and allowed to recover in complete medium 
for 18 hr [31].  Cells were then washed 3X in PBS and then treated with 10 nM uPA 
(Calbiochem), 20 nM stable recombinant PAI-1 (purified as previously described [32]), or 
uPA-PAI-1 complex formed by 30 min incubation of a 1:2 molar ratio of uPA and 
recombinant stable PAI-1. 
Indirect cell surface uPA activity assay - 1 x 10
4
 cells were plated in 96 well plates and 
plasminogen activation was assessed as previously described [33, 34]. Plasminogen (0.06 
μg/uL) (Chromogenix, Milan, Italy) in 100 mM Tris, 0.5% Triton X-100 (pH 8.8) was added 
to cells and incubated at room temperature for 30 min. Following incubation, 5 μl of 
supernatant was removed and added to another 96-well plate containing 74.8 μl buffer (100 
mM Tris, pH 8.8 with 0.5% Triton X-100) and 5 μl amiloride (6 mM stock solution) to 
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inhibit residual uPA activity. Plasmin chromogenic substrate (S-2251, Chromogenix, Milan, 
Italy) was then added to the well (100 μL total volume) and hydrolyzed by plasmin generated 
by plasminogen cleaved by uPA on the cell surface. The relative rate of plasmin activity was 
determined from the rate of color development at 405 nm. 
Lentiviral small hairpin RNA - pLKO.1, a nontargeted small hairpin control vector (Sigma)  
or shRNA vectors directed at uPA NM_002658 (TRCN0000051088, TRCN0000025089, 
TRCN0000025090, TRCN0000025091, TRCN0000025092) or PAI-1 NM_000602 
(TRCN0000052268, TRCN0000052269, TRCN0000052270, TRCN0000052271, 
TRCN000002272) were converted into lentiviral particles by the UNC-CH Vector Core 
Facility according to the protocol of Kafri and collegues [35]. For infection, cells were 
incubated with lentiviral particles supplemented with Polybrene and stably infected 
populations were selected and maintained in puromycin.  Knockdown efficiency for all 
sequences was assessed by quantitative PCR.  Populations infected with TRCN0000025901 
(designated uPAshRNA#4) as well as TRCN000052271 and TRCN000002272 (designated 
PAI-1shRNA#4 and PAI-1shRNA#5, respectively) were expanded for analysis.   
Quantitative PCR - Total RNA was isolated from serum starved cells via Trizol (Invitrogen), 
RNA was reverse transcribed using M-MLV reverse transcriptase (Invitrogen). Quantitative 
real-time PCR was performed using SYBR Green Dye (Applied Biosystems) and the 
following protocol: 5 min initial denaturation step at 95 °C, followed by 40 cycles of 95 °C 
for 20 s, 55 °C for 1 min, and 68 °C for 30 s. Using β-actin as a loading control, results were 
interpreted by the relative quantity method (ΔΔCt) using -actin as a loading control as 
previously described [36]. Primer sequences were: uPA: forward – 5 GGC AGC AAT GAA 
CTT CAT CAA GTT CC 3, reverse – 5 TAT TTC ACA GTG CTG CCC TCC G 3; PAI-1: 
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forward – 5 AAT CAG ACG GCA GCA CTG TC 3, reverse – 5 CTG AAC ATG TCG 
GTC ATT CC 3; uPAR: forward – 5 ACA GGA GCT GCC CTC GCG AC 3, reverse – 5 
GAG GGG GAT TTC AGG TTA GG 3; β-Actin: forward – 5 ATC ATG TTT GAG ACC 
TTC AA 3, reverse – 5 CAT CTC TTG CTC GAA GTC CA 3. 
Immunocytochemistry  - 5 x 10
4
 cells were plated in 2 well chamber slides (Lab-Tek).  After 
24 hours cells were washed with PBS and treated with medium containing 1% FBS for 24 
hours.  Cells were fixed in 4% paraformaldehyde, permeabilized with 0.25% Triton X-100 
and blocked for 30 minutes with PBS-T containing 1% BSA.  After blocking, cells were 
probed for either Ki67 (Abcam) or the active fragment of caspase 3 (Abcam) for 1 hour at a 
1:500 dilution.  Primary antibodies were detected by 10 minute incubation with biotinylated 
ant-rabbit IgG (Vector) followed by 10 minute incubation with streptavidin-HRP (Dako) and 
3 minutes of Dab stain (Dako).  Cells were counterstained with hematoxylin, mounted, and 
photomicrographs were obtained with an Olympus BX5W1 connected to an Olympus DB70 
microscope digital camera.  For each experiment the percentage of positively stained cells 
was assessed for 10 random 20X fields.    
Statistical Analysis - Statistical analysis was performed using a one sample student t test with 
normal distribution in experimental settings, which are normalized to a theoretical value of 
100% or 1 (for quantitative PCR).  A two sample student t test with a normal distribution was 
performed in experimental settings in which control values are not normalized to a 
theoretical mean of 100%.   
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Results 
MDA-MB-231 cells have a functional plasminogen activator system.  To assess the 
functionality of the plasminogen activator system in MDA-MB-231 cells, we utilized 
enzymatic inhibition of uPA and PAI-1 in 24 hr transwell invasion assays.  Inhibition of uPA 
with the small molecule inhibitor amiloride and a uPA inhibitory antibody decreased 
invasion approximately 30% (Figure 5.1).  By contrast, inhibition of PAI-1 with an inhibitory 
antibody increased invasion approximately 48% (Figure 5.1).  These results suggest that 
MDA-MB-231 cells, which express uPAR, uPA, PAI-1 [27] and LRP-1 protein [37], do 
exhibit a functional plasminogen activator system. Our findings differ from that of Liu et al. 
who reported that inhibition of both uPA and PAI-1 reduced invasion of the lung cancer cell 
line H292 in a 72 hr transwell assay [38].  
 Both PI3K and MAPK signaling positively regulate uPA and PAI-1 expression.  The 
PI3K and MAPK signaling pathways are key regulators of proliferation and apoptosis and 
are often activated in cancer cells.  Multiple studies have shown uPA is positively regulated 
by both PI3K and MAPK signaling.  In contrast, MAPK and PI3K signaling has been shown 
to either positively or negatively regulate PAI-1 expression depending on cell type [39-41].  
To determine the influence of these pathways on uPA and PAI-1 expression in the MDA-
MB-231 breast cancer cells, cells were treated for 24 hr with the MEK 1/2 inhibitor PD98059 
or PI3K inhibitor LY294002, RNA was isolated and reverse transcribed and subjected to 
quantitative PCR.  PI3K inhibition decreased uPA expression at both 10 and 25 M  
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Figure 5.1.  Effect of disruption of the plasminogen activator system on invasion and 
viability of MDA-MB-231 cells.  Cells were pre-treated with 0.2 mM amiloride, 20 g/ml m-anti-uPA, 
20 g/ml g-anti-PAI-1, or corresponding vehicle/control antibodies for 1 hour prior to seeding on matrigel 
coated inserts.  Cells invaded toward 10% FBS media for 24 hours (n=3). Data are expressed as mean +/- SD.   
*p<0.05 and **p<0.01, for cells treated with Amiloride, m-anti-uPA and g-anti-PAI-1 relative to DMSO, mIgG, 
and gIgG, respectively (n=3).   
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LY294002 (0.55 and 0.63 fold, respectively) and MEK1/2 inhibition decreased uPA 
expression at both 10 and 25M PD98059 (0.57 and 0.83 fold, respectively) (Figure 5.2A).  
Statistically significant inhibition of PAI-1 expression was achieved with 10 M LY249002 
(0.56 fold) and 25 M PD98059 (0.45 fold) (Figure 5.2B).  These results suggest that both 
MAPK and PI3K signaling positively regulate uPA and PAI-1 expression in the MDA-MB-
231 breast cancer cell line.   
 Establishment and characterization of MDA-MB-231 cells with stable shRNA 
mediated knockdown of uPA.  Multiple studies in cancer cell lines have linked binding of 
uPA to uPAR to activation of proliferative or anti-apoptotic signaling.  To expand upon these 
findings with the MDA-MB-231 breast cancer cell line, we established MDA-MB-231 cells 
with stable knockdown of uPA.  Cells were infected with a non-targeted lentiviral control 
(pLKO) or a lentivirus encoding short hairpin RNA directed against uPA mRNA 
(uPAshRNA#4); stable populations were selected and maintained in puromycin. Immunoblot 
of concentrated conditioned medium indicate clear knockdown of uPA using the 
uPAshRNA#4 construct (Figure 5.3A).  Interestingly, in addition to uPA knockdown, the  
uPA shRNA#4 construct also decreased the amount of PAI-1 antigen (Figure 5.3A).  The 
immunoblot results were complemented by quantitative PCR which indicated significant 
knockdown of uPA (59%, Figure 5.3B, left panel) as well as reduced expression of PAI-1 
(40%, Figure 5.3B, right panel) in uPAshRNA#4 cells.  The non-targeted pLKO virus did not 
alter uPA or PAI-1 message levels relative to untreated MDA-MB-231 cells (data not 
shown). The observed decrease in PAI-1 antigen and mRNA in the uPAshRNA#4 cells was 
unexpected.  However, based on our observations that the uPAshRNA#4 cells have 
decreased MAPK activity  
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Figure 5.2. PI3K and MAPK signaling modulate uPA and PAI-1 expression.  MDA-MB-
231 cells were serum starved for 24 hr and then treated for 24 hr with 10 μM or 25 μM PD98059, 10 μM or 25 
μM LY249002, or DMSO vehicle control in serum free media. Total RNA was extracted from serum starved 
cells and reverse transcribed.  uPA (upper panel) and PAI-1 (lower panel) expression were examined by 
quantitative PCR using a SYBR Green probe with -actin serving as a loading control.  Expression was 
evaluated by the 2-Ct method relative to DMSO treated cells. Data are expressed as mean +/- SD.  *p<0.05, 
**p<0.01 (n=3).   
 
uPA 
PAI-1 
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Figure 5.3.  Characterization of stable lentiviral mediated knockdown of uPA in MDA-MB-231 
cells.  (A) Cells expressing non-targeted pLKO control or uPAshRNA#4 lentivirus were serum starved for 24 
hours.  After 24 hours, conditioned media was collected and concentrated.  Equal amount of protein were 
loaded on polyacrylamide gels and uPA and PAI-1 antigen levels were assayed by immunoblot.  (B) Total RNA 
was extracted from serum starved cells and reverse transcribed.  uPA and PAI-1 expression were examined by 
quantitative PCR using a SYBR Green probe with -actin serving as a loading control.  Expression was 
evaluated by the 2-Ct method relative to pLKO cells.  Data are expressed as mean +/- SD. (uPA, n=5 and PAI-
1 n=3) **p<0.01  
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(Figure 5.6A, right panel) and that PAI-1 is positively regulated by MAPK signaling in 
MDA-MB-231 cells (Figure 5.2B), we hypothesize that the diminished PAI-1 levels in the 
uPAshRNA#4 cells may be a consequence of reduced MAPK signaling. 
Using an indirect cell surface uPA activity assay, we observed that the uPAshRNA#4 
cells exhibited significantly reduced uPA activity (22%) relative to pLKO control cells 
(Figure 5.4A).  In addition to its catalytic capacity, uPA has also been implicated in adhesion, 
notably by increasing the affinity of uPAR for the ECM protein vitronectin.  Relative to 
pLKO control cells, uPAshRNA#4 cells showed no change in adhesion to collagen IV, 
laminin, or fibronectin.  However, uPAshRNA#4 cells did exhibit decreased adhesion to 
vitronectin (Figure 5.4B).  Given the combined contributions of uPA to both matrix 
remodeling and adhesion, we wanted to examine the growth of uPAshRNA#4 in a three 
dimensional extracellular matrix.  When cultured for 6 days in a three dimensional matrix of 
basement membrane extract, uPAshRNA#4 cells exhibited significantly inhibited colony 
expansion relative to pLKO control cells (Figure 5.5).    
 Stable knockdown of  uPA in MDA-MB-231 cells reduces MAPK signaling and 
diminishes cell growth in low serum, but does not diminish cell viability in response to 
chemotherapeutic agents. Based on previous reports of the capacity of uPA to mediate 
proliferative and anti-apoptotic signaling, we examined the viability of the uPA stable 
knockdown cell line relative to the non-targeted pLKO cell line.  Growth curves generated by 
MTT indicated the uPAshRNA#4 cells exhibit diminished growth under low serum 
conditions (left panel, Figure 5.6A).  Supporting the findings of others [31], immunblot of 
whole cell lysates of uPAshRNA#4 cells also showed reduced ERK phosphorylation relative 
to pLKO controls, indicative of reduced MAPK signaling (right panel, Figure 5.6A).   
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Figure 5.4. Cell-surface associated uPA activity and extracellular matrix adhesion in 
MDA-MB-231 cells with stable uPA knockdown. (A) uPA activity of pLKO control and 
uPAshRNA#4 cells was assessed using indirect cell associated uPA activity assays.  20,000 cells were treated 
with plasminogen for 20 minutes and plasmin activity in the supernatant was assessed by cleavage of a 
chromogenic substrate.  Data are expressed as mean +/- SD (n=3).  *p<0.05, for uPAshRNA#4 cells relative to 
pLKO control cells.  (B) 25,000 cells pLKO or uPAshRNA#4 cells were plated in serum free media in 96 well 
plates pre-coated with 0.75 µg collagen IV, laminin, fibronectin, or vitronectin.  Cells were allowed to adhere 
for 1 hr at 37˚C.  Non-adherent cells were removed by washing with PBS and the relative amount of adherent 
cells was assayed by MTT.  Data are expressed as mean +/- SD (n=3).  *p<0.05 
 
* 
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Figure 5.5. Effect of stable uPA knockdown in MDA-MB-231 cells on growth in a three 
dimensional matrix. 3 x 104 pLKO (left panel) or uPAshRNA#4 cells (right panel) were seeded onto plates 
pre-coated with basement membrane extract (BME) and treated with complete medium containing 10% BME 
every 2 days.  Photomicrographs were obtained after 6 days in culture. 
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Interestingly, while it has been reported that transient uPA knockdown in MDA-MB-231 
cells sensitizes cell to apoptosis under serum free conditions [31] we observed no statistically 
significant sensitization of uPAshRNA#4 cells in response to apoptosis inducing 
chemotherapeutic agents paclitaxel, doxorubicin, or cisplatin relative to pLKO control cells 
(Figure 5.6B) 
 Inhibition of uPA and PAI-1 activity diminishes cell growth in low serum and growth 
in a three dimensional matrix.  While there is substantial evidence linking uPA binding of 
uPAR with cell viability and apoptosis, relatively little is known about the contribution of the 
catalytic activities of uPA and its cognate inhibitor PAI-1 on cancer cell viability.  To more 
closely assess the effect of uPA and PAI-1 inhibition on cell viability, both the MDA-MB-
231 and MDA-MB 436 breast cancer cell lines were treated with amiloride, a small molecule 
uPA active site inhibitor, or PAI-1 inhibitory antibody for a period of 7 days in low serum in 
a traditional two dimensional cell culture system.  Viability curves indicate that both uPA 
and PAI-1 inhibition have a significant inhibitory effect on the ability of MDA-MB-231 and 
MDA-MB-436 cells to grow under low serum conditions (Figure 5.7).  Given the established 
role of the PA system in degradation of the extracellular matrix, we next examined if the 
growth defects observed in low serum conditions translated to inhibited growth in a three 
dimensional matrix (Figure 5.8).  After 6 days in culture in the presence of complete media, 
we observed that MDA-MB-231 cells treated with amiloride (top right panel, Fig 5.8) 
exhibited significantly inhibited growth in basement membrane extract relative to control 
DMSO (top left panel, Figure 5.8).  PAI-1 inhibition also yielded a growth defect (bottom 
right panel, Figure 5.8) relative to control IgG (bottom left panel, Figure 5.8).   
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Figure 5.6. Effect of stable uPA knockdown on MDA-MB-231 cells viability in low serum and 
sensitivity to chemotherapeutic agents. (A) 10,000 cells were treated with 1% FBS media every 2 days 
and viability was assessed by MTT assay of triplicate samples immediately after initial treatment and at days 1, 
2, 3, and 7.  Viability is expressed relative to the MTT reading for each cell line at the start of the experiment.  
Data are expressed as mean +/- SD.  For day 7, **p<0.01 for uPAshRNA#4  (  ), relative to pLKO () (n=6).  
(B) 25,000 pLKO (black bars) and uPAshRNA#4 (white bars) cells in 96 wells plates were treated with 
complete media supplemented with 100 M Paclitaxel, 10 M Doxorubicin, 100 M Cisplatin, or DMSO 
vehicle control for 48 hours.  Relative viability in response to each chemotherapeutic reagent compared to 
DMSO alone was assessed by MTT of triplicate samples for each experiment (n=3).   
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Figure 5.7.  Effect of inhibition of uPA and PAI-1 activity on the viability of MDA-MB-
231 and MDA-MB-436 cells in low serum.  1 x 104 MDA-MB-231 (A) or MDA-MB-436 cells (B) 
were treated with 1% FBS media supplemented with DMSO (), 0.2 mM Amiloride (◊), 20g/ml gIgGm (■), 
or 20 g/ml g-anti-PAI-1 (□) every 2 days and viability was assessed by MTT assay of triplicate samples 
immediately after initial treatment and at days 1, 2, 3, and 7.  Viability is expressed relative to the MTT reading 
for corresponding wells at the start of the experiment.  Data are expressed as mean +/- SD (n=3 for (A), n=2 for 
(B)).  **p<0.01, for cells treated with amiloride relative to DMSO and g-anti-PAI-1 relative to gIgG and 
*p<0.05, for MDA-MB-436 cells treated with g-anti-PAI-1 relative to gIgG.   
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Figure 5.8. Effect of uPA and PAI-1 activity on growth in a three dimensional matrix.  3 x 104 
MDA-MB-231 cells were seeded onto plates pre-coated with basement membrane extract (BME) and treated 
with complete media containing 10% BME supplemented with DMSO (top left panel), 0.2 mM amiloride (top 
right panel), 20 g/ml gIgG (bottom left panel), or 20 g/ml g-anti-PAI-1 (bottom right panel) every 2 days.  
Photomicrographs were obtained after 6 days in culture.  
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Based on studies which demonstrate linkages of recognition of uPA and PAI-1 with MAPK 
and PI3K signaling [42, 43], we hypothesized that the treatments with amiloride and the PAI-
1 inhibitory antibody may alter both MAPK and PI3K signaling.  By immunoblot for 
phosphorylated ERK and Akt, we found that uPA and PAI-1 inhibition did yield decreases in 
both MAPK and PI3K activity for MDA-MB-231 cells.  Furthermore, we found that after 
removing endogenously bound uPA through mild acid wash, treatment of MDA-MB-231 
cells with pre-formed uPA-PAI-1 complex activated PI3K more strongly than uPA or PAI-1 
alone (Figure 5.9).  Together, these results suggest the recognition of uPA-PAI-1 complexes 
at the cell surface may promote signaling through not only MAPK, which has been 
previously demonstrated, but also PI3K. 
 Establishment and characterization of MDA-MB-231 cells with stable shRNA 
mediated knockdown of PAI-1.  Based on our findings using inhibitors of uPA and PAI-1 
activity, we next sought to establish MDA-MB-231 cells with stable PAI-1 knockdown.  
Cells were infected with a non-targeted lentiviral control (pLKO) or lentiviruses encoding 
short hairpin RNA directed against PAI-1 mRNA (PAI-1shRNA#4); stable populations were 
selected and maintained in puromycin. Immunoblot of concentrated conditioned media 
indicates clear knockdown of PAI-1 in the PAI-1shRNA#4 cells relative to pLKO control 
cells (Figure 5.10A).  The immunoblot results were complemented by quantitative PCR that 
indicated significant knockdown of PAI-1 (85%) in PAI-1shRNA#4 cells (left panel, Figure 
5.10B)).  The observed increase of uPA antigen in the conditioned media of the PAI-
1shRNA#4 cells (Figure 5.10A) is likely a consequence of reduced PAI-1 mediated clearance  
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 Figure 5.9. Effect of inhibition of uPA and PAI-1 activity on the activity of PI3K and 
MAPK.  Confluent MDA-MB-231 cells were serum starved for 24 hr, washed in PBS, and then treated for 24 
hours with serum-free medium supplemented with 0.2 mM Amiloride, 20 g/ml g-anti-PAI-1, or vehicle/gIgG 
controls for 24 hr. MAPK and PI3K activity was assessed by immunoblot for p-ERK and total ERK (A) or p-
Akt and total Akt (B). (C) Sub-confluent cells were subjected to mild acid wash to remove surface bound uPA 
and subsequently treated for 5 min with PBS, 10 nM uPA, 20 nM PAI-1, or pre-formed uPA-PAI-1 complex for 
5 minutes.  PI3K activity PI3K activity was assessed by immunoblot for p-Akt and total Akt on whole cell 
lysates.  Decimals represent fraction of phosphorylated ERK or Akt relative to total as assessed by 
densitometry.   
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Figure 5.10. Characterization of stable lentiviral mediated knockdown of PAI-1 in MDA-MB-
231 cells.  (A) Cells expressing non-targeted pLKO control and PAI-1shRNA#4 lentivirus were serum starved 
for 24 hr.  After 24 hr, conditioned media was collected and concentrated.  uPA and PAI-1 antigen levels were 
assayed by immunoblot.  (B) Total RNA was extracted from serum starved cells and reverse transcribed.  uPA 
and PAI-1 expression were examined by quantitative PCR using a SYBR Green probe with -actin serving as a 
loading control.  Expression was evaluated by the 2-Ct method relative to pLKO cells.  Data are expressed as 
mean +/- SD.  **p<0.01, for PAI-1shRNA#4 cells (uPA n=4 and PAI-1 n=6).   
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of uPA, as uPA expression was not affected by the PAI-1 targeted construct (right panel, 
Figure 5.10B).   Using an indirect cell surface uPA activity assay, we observed that PAI-I 
knockdown cells exhibited elevated uPA activity (370%) relative to pLKO control cells, as 
expected (Figure 5.11A).   In addition to its capacity to inhibit uPA activity, PAI-1 has been 
implicated in promoting the de-adhesion of cells from ECM proteins via proposed 
mechanisms ranging from specifically disrupting uPA/uPAR binding to vitronectin to 
generally mediating de-adhesion by catalyzing integrin internalization and destruction [15].  
PAI-1shRNA#4 cells exhibited significantly enhanced adhesion to collagen IV (1.8 fold), 
fibronectin (2.1 fold), and vitronectin (1.9 fold) relative to pLKO control cells.  Adhesion to 
laminin was not affected (Figure 5.11B).  The observed increased adhesion of PAI-
1shRNA#4 cells supports a role for PAI-1 to promote de-adhesion.          
Given the pronounced differences in uPA activity and adhesion of the PAI-
1shRNA#4 cell relative to pLKO controls, we further examined growth of these cells in a 
three dimensional matrix.  When cultured for 6 days in basement membrane extract PAI-
1shRNA#4 cells exhibited slightly reduced expansion as evidenced by a lower cell density 
(Figure 5.12).  This result contrasts with the traditional paradigms of the function of the PA 
system, which would predict elevated uPA activity would lead to enhanced expansion in a 
three dimensional matrix. 
Stable knockdown of PAI-1 in MDA-MB-231 cells with an alternate construct.  Given 
our novel observations with regard to the relationship of PAI-1 activity and cell viability, 
before moving forward we generated a secondary cell line with PAI-1 knockdown utilizing 
an alternate sequence.  MDA-MB-231 cells were treated with the alternate PAI-1 directed 
construct (PAI-1shRNA#5) and again selected in puromycin.  The alternate construct clearly  
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Figure 5.11. Cell-surface associated uPA activity and extracellular matrix adhesion in 
MDA-MB-231 cells with stable PAI-1 knockdown. (A) uPA activity of pLKO control and PAI-
1shRNA#4 cells was evaluated by indirect cell associated uPA activity assays.  2 x 104 cells were treated with 
plasminogen for 20 minutes and plasmin activity in the supernatant was assessed by cleavage of a chromogenic 
substrate (n=3).  *p<0.05, **p<0.01, for PAI-1shRNA#4 cells relative to pLKO control cells. (B) 2.5 x 104 cells 
pLKO or PAI-1shRNA#4 cells were plated in serum free medium in 96 well plates pre-coated with 0.75 µg 
collagen IV, laminin, fibronectin, or vitronectin.  Cells were allowed to adhere for 1 hr at 37˚C.  Non-adherent 
cells were removed by washing with PBS and the relative amount of adherent cells was assayed by MTT.   
 
 113 
 
 
 
 
 
 
 
Figure 5.12. Effect of stable PAI-1 knockdown in MDA-MB-231 cells on growth in a 
three dimensional matrix. 3 x 104 pLKO (left panel) or PAI-1shRNA#4 (right panel) cells were seeded 
onto plates pre-coated with basement membrane extract (BME) and treated with complete media containing 
10% BME every 2 days.  Photomicrographs were obtained after 6 days in culture. 
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reduced PAI-1 antigen in conditioned media and decreased PAI-1 mRNA by 70% (Figure 
5.13), without affecting uPA mRNA (data not shown).   
 Stable knockdown of PAI-1 in MDA-MB-231 cells diminishes cell growth in low 
serum and alters MAPK and PI3K signaling.  Based on our findings with uPA and PAI-1 
inhibition, we examined the viability of the two PAI-1 stable knockdown cell lines relative to 
the non-targeted pLKO cell line.  Growth curves generated by MTT indicated both PAI-
1shRNA#4 and PAI-1shRNA#5 cells exhibit diminished growth under low serum conditions 
(Figure 5.14). When MAPK and PI3K activity was assessed by immunoblot of 
phosphorylated ERK and Akt in the cell lines, both PAI-1shRNA#4 and PAI-1shRNA#5 
knockdown cell lines exhibited reduced MAPK (Figure 5.15A) and PI3K activity (Figure 
5.15B). Densitometric analysis of immunoblots for p-ERK versus total ERK and p-Akt 
versus total Akt showed that PAI-1shRNA#4 and PAI-1shRNA#5 cells exhibit an 
approximate 59% and 70% reduction in p-ERK signal and 80% and 75% reduction in p-Akt 
signal, respectively, relative to pLKO control cells. This data shows that MDA-MB-231 cells 
with stable PAI-1 knockdown have reduced overall viability relative to control cells under 
low serum conditions and this difference may be due to a combined reduction in MAPK and 
PI3K signaling.   
 MDA-MB-231 cells with stable PAI-1 knockdown are sensitized to apoptosis but do 
not have reduced proliferative capacity.  The growth curves show that MDA-MB-231 cells 
with PAI-1 knockdown exhibit reduced growth under low serum conditions.  In low serum 
conditions, the overall phenotype could be attributed to either a defect in the proliferative 
capacity of the cells or increased cell death due to apoptosis.  To address which of these  
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Figure 5.13. Characterization of MDA-MB-231 cells expressing PAI-1shRNA#5. Total 
RNA was extracted from serum starved cells and reverse transcribed. PAI-1 expression was examined by 
quantitative PCR using a SYBR Green probe with β-actin serving as a loading control. Expression was 
evaluated by the 2-ΔΔCt method for PAI-1shRNA#5 relative to pLKO cells. Data are expressed as mean +/- SD 
(n=3).  **p<0.01. Inset. pLKO control and PAI-1shRNA#5 cells were serum starved for 24 hr. After 24 hr, 
conditioned media was collected and concentrated. PAI-1 antigen levels were assayed by immunoblot. 
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Figure 5.14. Effect of stable PAI-1 knockdown in MDA-MB-231 cells on viability in low 
serum.  1 x 104 cells were treated with 1% FBS media every 2 days and viability was assessed by MTT assay 
of triplicate samples immediately after initial treatment and at days 1, 2, 3, and 7.  Viability is expressed relative 
to the MTT reading for each cell line at the start of the experiment.  Data are expressed as mean +/- SD.  For 
day 7, **p<0.01 for PAI-1shRNA#4 (□, n=4), and PAI-1shRNA#5 (■, n=3), relative to pLKO (, n=6).   
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Figure 5.15. Effect of stable PAI-1 knockdown on PI3K and MAPK activity.  Confluent 
cells were serum starved for 24 hr and MAPK and PI3K activity was assessed by immunoblot of whole cell 
lysates for p-ERK and total ERK (A) or p-Akt and total Akt (B).  Percentage p-ERK/ERK and p-Akt/Akt signal 
in PAI-1shRNA#4 and PAI-1shRNA#5 relative to pLKO control cells was further assessed by densitometry of 
immunoblots from two independent experiments. Data are expressed as mean +/- SD (n=2).  *p<0.05.  
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phenomena contributes most to the reduced growth of PAI-1shRNA#4 and PAI-1shRNA#5 
cells relative to the pLKO control, cells were treated for 24 hours in low serum conditions 
and then stained for either the proliferation marker Ki67 or the active fragment of Caspase-3, 
a key initiator of the apoptotic proteolytic cascade.  When compared to both wild type MDA- 
MB-231 and pLKO cells, the PAI-1 knockdown cells exhibited no decrease in Ki67 staining 
(Figure 5.16A).  Given that no differential was observed in the four cell lines, as a control, 
late passage human umbilical vein endothelial cells (HUVECs) were stained for Ki67.  Only 
43% of these late passage HUVEC stained positive for Ki67 (data not shown).  However, 
both PAI-1shRNA#4 and PAI-1shRNA#5 cell lines had increased active Caspase-3 staining 
(38% and 34%, respectively) relative to both wild type MDA-MB-231 cells and pLKO cells 
(8% and 9%, respectively) (Figure 5.16B).  These results suggest that the growth defect 
observed under low serum conditions for the PAI-1 knockdown cells is likely a consequence 
of increased cell death due to apoptosis.   
 PAI-1 knockdown sensitizes MDA-MB-231 cells to apoptosis-inducing 
chemotherapeutic agents.  To further examine our hypothesis that PAI-1 knockdown 
sensitizes cells to apoptosis, pLKO, PAI-1shRNA#4, and PAI-1shRNA#5 cells were treated 
with the microtubule stabilizing agent paclitaxel, the DNA intercalating agent doxorubicin, 
and DNA crosslinking agent cisplatin for 48 hours in complete media.  As assayed by MTT, 
there was significantly more cell death in response to all three agents in the PAI-1 
knockdown cell lines relative to pLKO control cells, except for the response of PAI-
1shRNA#5 cells to cisplatin which was not statistically significant (Figure 5.17A).  Wild 
type MDA-MB-231 and pLKO cells did not exhibit differential sensitivity to the 
chemotherapeutic drugs (data not shown).  pLKO and PAI-1shRNA#4 cells were also  
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Figure 5.16.  Assessment of basal proliferative capacity and apoptosis in MDA-MB-231 cells 
with stable PAI-1 knockdown.  50,000 cells were plated in 2 well chamber slides.  24 hours post plating 
cells were treated with 1%FBS media for 24 hours, fixed in 4% paraformaldehyde, and stained for Ki67 (A) to 
assess proliferative capacity or active Caspase-3 (B) to assess apoptosis.  For each experiment, percent 
positivity was determined by counting 10 random fields at 20X magnification.  Data are expressed as mean +/- 
SD (n=3). **p<0.01, for PAIshRNA#4 (gray bars) and PAI-1shRNA#5 (dark gray bars) relative to wild type 
MDA-MB-231 cells (black bars) and well as pLKO control cells (white bars). 
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cultured in a three dimensional matrix of basement membrane extract in the presence of 
paclitaxel, doxorubicin, and cisplatin for 6 days.  Relative to the pLKO cells in response to 
paclitaxel and cisplatin, there was significantly more death of the PAI-1shRNA#4 cells, 
evidenced by rounding and detachment from the basal culture surface.  In response to 
doxorubicin, while some pLKO cells remained viable in culture, after 6 days in culture only 
cellular fragments remained of the PAI-1shRNA#4 cells (Figure 5.17B).  Collectively, these 
results indicate that stable knockdown of PAI-1 significantly sensitizes MDA-MB-231 cells 
to chemotherapeutic agents.   
 Inhibition of PAI-1 activity sensitizes MDA-MB-436 cells to apoptosis inducing 
chemotherapeutic agents.  As discussed previously, MDA-MB-436 cells displayed growth 
inhibition in low serum conditions similar to the MDA-MB-231 cells.  To further assess the 
role of PAI-1 in sensitivity to chemotherapeutic agents these cells were also treated with 
paclitaxel, doxorubicin, and cisplatin in the presence of control goat IgG or PAI-1 inhibitory 
antibody.  The MDA-MB-436 cells were more sensitive to these agents that the MDA-MB-
231 cells (data not shown).  However, treatment with all three agents at a lower concentration 
(1 M) revealed that inhibition of PAI-1 activity significantly increased their sensitivity to 
paclitaxel, doxorubicin, and cisplatin relative to control goat IgG (Figure 5.18).   
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Figure 5.17.  Chemotherapeutic sensitivity of MDA-MB-231 cells with stable PAI-1 knockdown. 
(A) 2.5 x 104 pLKO (black bars), PAI-1shRNA#4 (white bars), and PAI-1shRNA#5 (gray bars) cells in 96 wells 
plates were treated with complete media supplemented with 100 M Paclitaxel, 10 M Doxorubicin, 100 M 
Cisplatin, or DMSO vehicle control for 48 hr.  Relative viability in response to each chemotherapeutic reagent 
compared to DMSO alone was assessed by MTT of triplicate samples for each experiment (n=3).  *p<0.05, 
**p<0.05, for PAI-1shRNA#4 and PAI-1shRNA#5 relative to pLKO control cells.  (B)  30,000 pLKO and PAI-
1shRNA#4 cells were seeded onto plates pre-coated with basement membrane extract (BME) and treated with 
complete media containing 10% BME supplemented with 100 M Paclitaxel, 10 M Doxorubicin, or 100 M 
Cisplatin every 2 days.  Photomicrographs were obtained after 6 days in culture. 
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Figure 5.18.  Sensitization of MDA-MB-436 cells to chemotherapeutic agents by PAI-1 activity 
inhibition.  25,000 MDA-MB-436 cells in 96 wells plates were treated with complete media supplemented 
with 1M Paclitaxel, 1M Doxorubicin, 1M Cisplatin, or DMSO vehicle control with gIgG control antibody 
(black bars) or goat PAI-1 inhibitory antibody(white bars) for 48 hours.  Relative viability in response to each 
chemotherapeutic reagent compared to DMSO alone was assessed by MTT of triplicate samples for each 
experiment.  Data are expressed as mean +/- SD (n=2).  *p<0.05, **p<0.01.    
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Discussion 
 The plasminogen activator system has proven to play a complex role in tumor biology 
related to angiogenesis, tumor cell motility, and viability.  However, likely due to the 
complex interplay of uPAR, the protease uPA, the serpin PAI-1, and the LRP-1 co-receptor, 
as well the interplay between this system with integrins and adhesion to the ECM, conflicting 
results emerge depending on experimental context.  Notably, most of the conflicting data 
centers on the biological activity of the serpin, PAI-1.  For example, with regard to 
angiogenesis, Soff et al. showed that expression of PAI-1 cDNA in prostate carcinoma cells 
inhibits angiogenesis [23], while studies by Bajou et al. showed that absence of PAI-1 
prevents tumor vascularization [22]. Furthermore, conflicting results also have been reported 
regarding the role of PAI-1 in tumor cell motility. In cell motility assays on vitronectin, 
Kjoller et al. reported PAI-1 inhibits motility of epidermoid carcinoma Hep-2 cells [44] 
whereas Palmieri et al. reported PAI-1 promotes motility [45].   In this report, using the 
MDA-MB-231 breast cancer cell line, we utilized the transwell invasion assay that 
incorporates motility and proteolytic capacity as a surrogate for a metastatic phenotype.  In 
this experimental context, inhibition of uPA activity leads to reduced invasion whereas PAI-1 
inhibition promotes invasion.  These findings correlate with the traditional paradigm of the 
function of the PA system in cancer cell metastasis.   
 Outside of the influence of PAI-1 in angiogenesis and cell motility, an emerging 
complexity in the field is the influence of PAI-1 on tumor cell viability.  There are numerous 
reports suggesting that uPA/uPAR activates signaling pathways associated with proliferation 
and protection from apoptosis in cancer cells [46-50]. This signaling capacity of uPA/uPAR 
is important given the observed up-regulation of uPA and uPAR in multiple types of cancer 
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[14, 51-53].   It is possible that our degree of uPA knockdown was not sufficient to sensitize 
cells to apoptosis through reduced MAPK signaling.  
 What remains unclear is how PAI-1, in the presence of uPA, modulates signaling 
associated with proliferation and/or apoptosis. This question is especially relevant to breast 
cancer, as elevated levels of both uPA and PAI-1 antigen are strongly associated with poor 
prognosis [21].  One might expect PAI-1 would logically inhibit uPA/uPAR mediated 
proliferative and/or anti-apoptotic signaling and therefore lead to reduced viability of a 
cancer cell.  However, there is growing evidence supported by our findings here, that PAI-1 
can instead actually promote cancer cell viability.   
 Webb et al. reported that in MCF-7 breast cancer cells, recognition of purified uPA-
PAI-1 complex at the cell surface stabilized ERK phosphorylation and was associated with 
increased cell viability in serum free medium relative to treatment with uPA or PAI-1 alone 
[42].  In this report, we show that in the inverse experiment, disruption of uPA-PAI-1 
complex formation with both the uPA inhibitor amiloride and an antibody directed at the 
reactive center loop of PAI-1 results in reduced MAPK activity, reduced viability in serum 
free media, and reduced growth of cells in low serum conditions over a 7-day period.  
Furthermore, we report that in addition to ERK phosphorylation, inhibiting uPA-PAI-1 
complex formation was also associated with decreased Akt phosphorylation whereas 
treatment of cells with pre-formed uPA-PAI-1 complex resulted in increased Akt 
phosphorylation. Phosphorylation of Akt is a key indicator of activation of the anti-apoptotic 
PI3K pathway and suggests the effects of uPA-PAI-1 complex formation and recognition at 
the cell surface are related to protection from apoptosis.   
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 We also aimed to evaluate the phenotype of cells cultured in a three dimensional 
matrix with uPA and PAI-1 inhibition because a combination of cell proliferation, matrix 
adhesion, and proteolytic activity all contribute to colony expansion.  In three-dimensional 
culture, inhibition of uPA activity with amiloride significantly inhibited colony expansion in 
matrigel likely as a combined consequence of decreased proliferative/anti-apoptotic signaling 
and decreased capacity for matrix degradation.  Interestingly, despite the potential for 
increased capacity for matrix degradation, antibody-mediated inhibition of PAI-1 activity 
also partially decreased expansion in a three-dimensional culture, again likely a consequence 
of reduced proliferative capacity and/or increased sensitivity to apoptosis. 
 Given the limitations of enzymatic inhibition, we aimed to establish MDA-MB-231 
derivative cell lines with stable shRNA mediated knockdown of either uPA or PAI-1 in 
parallel to examine the resulting proliferative/anti-apoptotic phenotype.  As expected, relative 
to the finding of Ma et al [31], cells with stable knockdown of uPA exhibited reduced ERK 
phosphorylation.  Ma et al further suggested that uPA knockdown sensitizes MDA-MB-231 
cells to apoptosis.  However, we did not observe sensitization to apoptosis inducing 
chemotherapeutic agents.  This discrepancy may be a result of knockdown strategy as the 
previous study utilized transient knockdown whereas we generated a stable population.  
  Intriguingly, uPA knockdown unexpectedly led to a decrease in PAI-1 mRNA 
expression.  We hypothesize the reduced PAI-1 expression is a consequence of reduced ERK 
phosphorylation as PAI-1 expression is positively regulated by MAPK activity in the parental 
MDA-MB-231 cells.  As observed with uPA enzymatic inhibition, uPA knockdown 
significantly inhibited growth of cells in low serum and the expansion of cells in three-
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dimensional culture.  However, we did not observe sensitization to apoptosis inducing 
chemotherapeutic agents.   
 Cells with stable knockdown of PAI-1 exhibited an inhibited ability to grow in low 
serum conditions similar to that observed with uPA knockdown as well as a decrease in 
expansion in a three dimensional matrix.  Interestingly, PAI-1 knockdown resulted in a 
pronounced reduction of both ERK and Akt phosphorylation.  This finding correlates with 
the recent results of Romer et al who demonstrated fibrosarcoma cell lines derived from PAI-
1 knockout mice, as well as with wild type fibrosarcoma lines treated with PAI-1 RNAi, 
exhibit reduced Akt phosphorylation relative to controls [54].   
 Because cell growth in low serum conditions represents a balance of proliferation 
versus apoptosis, we wanted to assess more closely the predominant process affecting growth 
in low serum conditions secondary to PAI-1 knockdown.  Notably, PAI-1 knockdown did not 
significantly inhibit expression of Ki67, a marker of cell cycling [55].  By contrast, PAI-1 
knockdown did significantly increase activation of the cysteine protease Caspase-3, a key 
initiator of apoptosis [56]. Taken together with the decreased phosphorylation of both ERK 
and Akt, our results suggest PAI-1 can protect cells from spontaneous apoptosis. Based on in 
vitro activity and binding assays, it has been previously suggested that PAI-1, which is a 
serine protease inhibitor, may protect cells from apoptosis intracellularly via direct inhibition 
of Caspase-3 cysteine protease activity in vascular smooth muscle cells [57].  However, the 
observed increase activation of Caspase-3 in this report suggests the anti-apoptotic effects of 
PAI-1 are upstream of direct inhibition of Caspase-3.   The observed viability defect 
secondary to antibody mediated PAI-1 inhibition in low serum conditions for both MDA-
MB-231 and MDA-MB-436 breast cancer cells suggests PAI-1 exerts its anti-apoptotic 
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effects by initiating signaling extracellularly, possibly through the LRP-1 co-receptor that has 
been demonstrated to exert anti-apoptotic signaling capacity through PI3K [58-59].  It is also 
interesting that MAPK and PI3K signaling which are activated by PAI-1 at the cell surface, 
also positively regulate expression of uPA and PAI-1, potentially creating a feedback loop.  
Figure 5.19 diagrams our working model of how recognition of PAI-1, and specifically, uPA-
PAI-1 complexes at the cell surface may initiate signaling through LRP-1 and also positively 
regulate uPA and PAI-1 expression.   
 Given the observed increased sensitivity to spontaneous apoptosis, we further 
evaluated the sensitivity of cells with PAI-1 knockdown to apoptosis-inducing agents.  
Endogenous PAI-1 was previously shown to be protective against etoposide-induced 
apoptosis in murine fibrosarcoma cell lines [54, 60]. In addition, purified PAI-1 has been 
demonstrated to protect the human prostate cancer cell line PC-3 and the human 
promeylocytic leukemia cell line HL-60 from CPT-induced apoptosis but pre-formed uPA-
PAI-1 complex did not [61]. Here we report that PAI-1 knockdown in MDA-MB-231 cells, 
which also express uPA, significantly sensitizes the cells to apoptosis-inducing agents 
paclitaxel, doxorubicin, and cisplatin.  We also demonstrate that MDA-MB-436 breast cancer 
cells can be sensitized to apoptosis inducing chemotherapeutic drugs with a PAI-1 inhibitory 
antibody.  It is notable that these three agents work through distinct mechanisms.  While 
paclitaxel is a microtubule stabilizing agent that induces apoptosis secondary to G2/M arrest 
[62-63], doxorubicin is thought to mainly induce apoptosis through DNA intercalation with 
subsequent Topoisomerase II mediated double strand breaks [64], and cisplatin induces 
apoptosis secondary to the formation of DNA adducts [65].  Given the importance of PAI-1 
expression as a diagnostic marker in breast cancer and its potential utility in determining  
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Figure 5.19.  Working model of MAPK and PI3K signaling modification by PAI-1.  
When uPAR/uPA/PAI-1 complexes are recognized on the cell surface by LRP, this triggers MAPK and PI3K 
signaling, with LRP functioning as the signaling module via an unknown intracellular co-factor.  Activation of 
these pathways also positively regulates uPA and PAI-1 expression.   
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appropriate treatment strategies, it is also notable that all three of these agents are utilized in 
adjuvant chemotherapeutic regimens for breast cancer patients. 
 Taken together, our findings suggest that the observed elevation of uPA and PAI-1 
antigen in breast cancer may represent more than a poor prognostic marker.   Instead, our 
findings suggest the presence of both uPA and PAI-1 in the tumor microenvironment may 
directly protect breast cancer cells from apoptosis.  Furthermore, we report for the first time 
that PAI-1, in a cell based model in which uPA is also present, protects breast cancer cells 
from spontaneous apoptosis in low serum and PAI-1 protects cells from the cytotoxic effects 
of three distinct chemotherapeutic agents:  paclitaxel, doxorubicin, and cisplatin.  Our 
findings further illustrate the importance of assessment of uPA and PAI-1 levels in breast 
cancer when determining treatment strategies and the need for continued research toward 
utilization of PAI-1 as a potential therapeutic target.   
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 Serine proteases and serine protease inhibitors (serpins) have long been recognized 
for their role in hemostasis and fibrinolysis.  The balanced activities of thrombin, which 
activates fibrinogen to form fibrin clots, and APC, which inactivates other pro-coagulant 
factors, allows for tightly regulated deposition of fibrin clots at the site of a vessel injury.  To 
resolve fibrin clots, the serine proteases uPA and tPA activate plasmin, which catalyzes 
degradation of fibrin.  To prevent excessive fibrinolysis, uPA and tPA activity is balanced by 
the inhibitory capacity of PAI-1.  Outside of the vasculature, thrombin, APC, uPA, and PAI-
1 have proven to also participate in multiple processes involved in cancer growth and 
metastasis.  In this dissertation, I examined the potential contributions of APC, uPA, and 
PAI-1 to breast cancer pathophysiology.  I first focused on confirming the pro-angiogenic 
capacity of APC and determining the mechanism by which APC also promotes breast cancer 
cell invasion.  Second, I examined the effects of uPA and its inhibitor PAI-1 and breast 
cancer cell viability.   
 While there have been previous reports on the ability of APC to promote 
angiogenesis, there is some debate over the physiological relevance of previous reports due 
to use of high concentrations of APC.  In demonstrating that APC can promote HUVEC 
chemotaxis, invasion, and tube formation at low APC concentrations (1-10 μg/ml) we 
provide further evidence that APC is pro-angiogenic.  Furthermore, studies with the ex vivo 
aortic ring sprouting assay confirm what others have suggested, that APC induced 
angiogenesis is dependent upon MMP activity and EGFR transactivation.   
 Although extensive work has been performed regarding the role of APC in 
angiogenesis, there are few previous reports on the capacity of APC to promote cancer cell 
motility.  Originally, it was suggested that APC promotes motility of ovarian and 
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choriocarcinoma cancer cells by binding to PAI-1, thereby increasing uPA catalytic activity.  
In contrast, in breast cancer cells, I showed that APC promotes invasion independently of 
uPA and PAI-1 activity.  The dependency of APC promoted cancer cell invasion on MMP 
activity and EGFR trans-activation parallels the mechanism demonstrated with endothelial 
cell motility by others.  However, I found that while MMP activity is required for breast 
cancer cell invasion, APC does not significantly up-regulate MMP expression as it does in 
endothelial cells.  Furthermore, I am first to report that APC activates MAPK and PI3K 
signaling in breast cancer cells, and that activation of these pathways is required for APC 
induced invasion.   
 Given the dearth of previous work on APC induced cancer cell migration, many 
questions remain as to the relative significance of APC to breast cancer pathology and the 
mechanism by which APC promotes cancer cell invasion.  As reviewed in Chapter II, 
increased thrombin activity has been demonstrated in a wide variety of human cancers.  In 
mouse models of cancer, thrombin activity has also been linked to metastasis.  Despite the 
fact that thrombin activates APC, much less is known about APC activity in human cancers 
or how APC may influence metastasis.  To start, it would be interesting to perform 
immunohistochemistry on breast tumor biopsies and matched normal tissue to determine if 
APC levels are elevated in tumor samples and if so, where APC is localized.  Furthermore, it 
would be useful to expand my study to alternate human and mouse breast cancer cell lines.  
This would require characterization of these cell lines as to their expression of PAR-1, 
EPCR, and EGFR as these three receptors appear necessary for APC promoted invasion.  In 
addition to invasion, I demonstrated that APC activates both MAPK and PI3K signaling.  
These pathways are key regulators of cell proliferation and sensitivity to apoptosis.  It would 
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therefore be interesting to examine the effects of APC on proliferation of breast cancer cells 
and sensitivity to apoptosis.   
 Much remains to be studied about the precise mechanism whereby APC activates 
MAPK and PI3K signaling.  First, my study would be improved by the use of shRNA to 
stably knockdown EPCR, PAR-1, and EGFR to more stringently examine the requirement of 
all three receptors for APC induced signaling.  Furthermore, the generation of a mouse breast 
cancer cell line that expresses PAR-1 and EGFR with stable EPCR knockdown could be 
utilized in mouse models, such as mammary fat pad injection, to study primary tumor growth 
and metastasis.   
 This work and that of others support a mechanism in which EPCR localizes APC to 
the cell surface and APC cleaves PAR-1.  It remains unclear how PAR-1 can trans-activate 
EGFR and how PI3K can be activated by APC.  It is possible that PAR-1 cleavage by APC 
activates  or / subunits which activate c-Src.  c-Src can mediate phosphorylation of the 
cytoplasmic tail of EGFR.  An alternative mechanism whereby PAR-1 can activate EGFR is 
via activation of the TNF-alpha converting enzyme (TACE; ADAM-17) that processes 
heparin bound-EGF (HB-EGF).  HB-EGF would bind to the ligand-binding domain of 
EGFR, leading to the phosphorylation of the receptor and activation of Ras.  Either 
mechanism could account for PI3K activation, as c-Src and Ras can activate PI3K.    
 In Chapter V, I examined the role of uPA and PAI-1 in breast cancer cell viability 
utilizing MDA-MB-231 and MDA-MB-436 breast cancer cells.  The overall goal of this 
project was an attempt to understand the breast cancer “PAI-1 paradox.”  Multiple clinical 
studies have demonstrated that elevation of both uPA and PAI-1 in breast cancer is 
associated with poor prognosis.   It is logical that elevated uPA would be a poor prognostic 
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indicator given the numerous capacities of uPA to promote angiogenesis, tumor cell invasion, 
as well as induce cancer cell proliferation (reviewed in Chapter II).  However, it is unclear 
why elevated PAI-1, which would presumably function to counteract uPA, is a poor 
prognostic indicator.  Others have focused on the potential pro-angiogenic functions of PAI-1 
to explain the PAI-1 paradox.  Taking a different approach, I hypothesized that PAI-1 would 
directly modulate signaling that promotes the overall viability of the breast cancer cells.   
 There have been few previous reports on the dual effects of uPA and PAI-1 on breast 
cancer cell physiology.  A central limiting factor in previous research is the labile nature of 
PAI-1.  If it does not react with a protease, PAI-1 undergoes spontaneous transition to a latent 
state.  In vitro, active PAI-1 has a half-life of between 1 and 2 hours [reviewed in 1].  
Furthermore, many breast cancer cells, as well as other cancer cell types, do not make PAI-1.  
Therefore, previous research has relied heavily on the use of purified PAI-1 that is added to 
cells.  Given the latency transition of PAI-1 within 1 to 2 hours, this limits the scope of 
analysis of the role of PAI-1 on cancer cell physiology.  While a mutated form of PAI-1 that 
does not undergo latency has been generated, its protease inhibitor activity is slightly altered 
from wild type PAI-1 [2].  To avoid these difficulties, we relied heavily on MDA-MB-231 
breast cancer cells and also utilized MDA-MB-436 breast cancer cells as they generate their 
own uPA and PAI-1, as well as express uPAR, the uPA receptor.   
 There is extensive- yet sometimes conflicting - literature investigating the role of uPA 
and PAI-1 in invasion and adhesion to the ECM.  Using active site inhibitors, I showed that 
inhibition of uPA activity decreases invasion through basement membrane extract whereas 
inhibition of PAI-1 activity promotes invasion.  With regard to adhesion, using a stable 
knockdown approach, my data supports previous studies suggesting uPA promotes adhesion 
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to vitronectin by increasing the affinity of uPAR to vitronectin.  Alternatively, there is some 
debate in the field as to whether PAI-1 promotes de-adhesion to vitronectin specifically, by 
competing for the same binding site as uPA, or promotes de-adhesion to multiple matrix 
proteins by disrupting uPAR/integrin complexes.  Utilizing stable PAI-1 knockdown, my 
data indicates PAI-1 is generally de-adhesive, as PAI-1 knockdown resulted increased 
adhesion to collagen IV, fibronectin, and vitronectin.   
 Previous studies utilizing transient knockdown technique suggest uPA mediates 
proliferative signaling through activation of MAPK in breast cancer cells.   Here, utilizing a 
stable knockdown approach, I show that uPA knockdown does decrease MAPK signaling as 
well as demonstrate that uPA knockdown inhibits cell growth in low serum conditions over a 
seven day period.  Interestingly, in partial contrast with previous reports that uPA promotes 
anti-apoptotic signaling, I did not observe sensitization to chemotherapeutic agents.  This 
discrepancy is likely a consequence of either different degrees of uPA knockdown or 
different experimental approaches.  This result is also surprising, given the observed 
knockdown of PAI-1 in the uPA knockdown cells.  However, the cells may have a threshold 
level of PAI-1 that remains protective. To further contribute to the existing literature, it 
would be interesting to generate stable knockdown of uPA in other breast cancer cell lines, 
and further characterize what signaling pathways are altered as well as perform flow 
cytometry to determine if stable uPA knockdown slows rates of DNA synthesis, as one might 
expect downstream of reduced MAPK signaling.   
 What previous studies focused on uPA have not addressed, is the role of uPA 
proteolytic activity on cancer cell viability.  Using a small molecule uPA inhibitor, I show 
that in fact, inhibition of uPA activity decreases growth of cells in low serum conditions and 
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has inhibitory effects on both MAPK and PI3K signaling.  Inhibition of uPA activity could 
have many downstream consequences that could account for this effect, notably activation of 
MMPs and plasmin which can activate growth factors (reviewed in II).  However, I 
hypothesized that the effects of inhibition of uPA activity were a consequence of reduced 
binding of PAI-1 to uPA at the cell surface.   
 My initial experiments using a PAI-1 inhibitory antibody to examine changes in 
MAPK and PI3K signaling and cell growth in low serum supported my hypothesis.  My 
hypothesis was further supported finding that stable knockdown of PAI-1 lead to decreased 
MAPK and PI3K signaling as well as decreased cell growth in low serum conditions.  
Interestingly, experiments in low serum conditions indicated that Ki67 expression did not 
decrease while active Caspase-3 staining increased.  One might expect decreased MAPK 
signaling would decrease Ki67 expression.  However, because Ki67 is a general marker of 
proliferation, further experiments should be pursued to determine if PAI-1 knockdown 
decreases proliferation.  This could be achieved by examining BrdU incorporation and flow 
cytometry to examine DNA synthesis activity and cell cycle disribution.  The increased 
activation of Caspase 3 strongly indicated that PAI-1 knockdown does sensitize breast cancer 
cells to apoptosis.  Given increased activation of Caspase 3 in low serum conditions, I 
hypothesized that PAI-1 knockdown would sensitize cells to apoptosis inducing 
chemotherapeutic agents.  This hypothesis was supported, as MDA-MB-231 cells with PAI-1 
knockdown were significantly sensitized to paclitaxel, doxorubicin, and cisplatin.  This 
finding represents the first demonstration to date that PAI-1 knockdown can sensitize cancer 
cells to chemotherapeutics that are used clinically to treat breast cancer.   
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 Clearly, our findings need to be expanded to more breast cancer cell lines.  My 
finding that PAI-1 inhibition reduced the growth of MDA-MB-436 breast cancer cells and 
sensitized them to low dose chemotherapeutics suggests my observations apply to a separate 
uPA and PAI-1 expressing breast cancer cell line.  I am currently generating MDA-MB-436 
cells with stable PAI-1 knockdown for future analysis.  As an alternative approach, it would 
be interesting to take a reverse approach and stably express wild type PAI-1 in another breast 
cancer cell line which expresses uPAR and uPA and examine the consequent effects on 
viability.   
 Mechanistically, many questions still remain as to how PAI-1 could be protective 
against apoptosis in breast cancer cells.  One study has suggested that PAI-1 prevents 
apoptosis intracellularly by inhibiting Caspase 3.  My finding of differential Caspase 3 
activation in PAI-1 knockdown cells, as well as the observed effects of an extracellular PAI-
1 inhibitory strongly contradict this hypothesis.  Others have predicted that PAI-1 should 
inhibit PI3K signaling as a function of dissociating or destroying uPA/uPAR/integrin 
complexes, thereby dissociating integrins from matrix ligands.  Again, my demonstration that 
PAI-1 knockdown cells have instead decreased PI3K activity contradicts this hypothesis.  
The most likely mechanistic target for PAI-1 anti-apoptotic activity is the LRP-1 co-receptor 
responsible for clearing uPA/PAI-1 complexes at the cell surface.  Recently, the LRP-1 co-
receptor has been reported to protect fibroblast from apoptosis [3].  It will be intriguing to see 
if stable knockdown of LRP-1 could mimic the phenotype of PAI-1 knockdown cells.  I have 
obtained LRP-1 shRNA constructs for this future project. 
 Determining the relevance of these findings to breast cancer pathology will require 
further investigation.  While there are conflicting reports, it is generally understood that the 
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tumor cells are not the primary source of PAI-1 in the breast tumor microenvironment.  It 
would therefore be interesting to establish a co-culture system in which breast cancer cells 
with PAI-1 knockdown are cultured with adipocytes or fibroblasts which can continuously 
synthesize PAI-1.  In this system, one could analyze the effect of exogenous PAI-1 on breast 
cancer cells.  Future mouse models would also go far to elucidate the overall contribution of 
PAI-1 to tumor biology.  This would best be achieved by the generation of control mouse 
breast cancer tumor cell lines and cells with stable PAI-1 knockdown.  These tumors could 
be injected into the mammary fat pad of syngeneic wild-type mice as well as PAI-1 knockout 
mice to investigate the contributions of tumor produced versus host produced PAI-1 on 
tumor growth and metastasis.   
 Therefore, in conclusion of this dissertation, I have demonstrated that the hemostatic 
serine protease APC promotes both angiogenesis and invasion of breast cancer cells by a 
mechanism dependent upon MMP activity, EGFR activation, and activation of PI3K and 
MAPK signaling.  I also demonstrate that APC promotes cancer cell invasion independent of 
the fibrinolytic serine protease uPA and its inhibitor PAI-1, which was previously suggested.  
Next, utilizing inhibitory and stable knockdown strategies, I have shown that uPA induces 
proliferative signaling not only through binding of its receptor uPAR, as has been previously 
shown, but also through its catalytic capacity, which is required for PAI-1 binding at the cell 
surface.  Lastly, I provided evidence that the serine protease inhibitor PAI-1 modulates both 
proliferative and apoptotic responses and is protective against apoptosis inducing 
chemotherapeutic agents.   
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